,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,RFX4,,ENSG00000111783,Regulatory factor X4,12,106582907-106762803,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA050527,Enhanced,,Approved,Nucleus,,Tissue enriched,Group enriched,236,cerebral cortex: 30.8;testis: 135.8,prostate: 0.3,Cell line enriched,13.0,AF22: 47.1
1,MMD2,PAQR10,ENSG00000136297,Monocyte to macrophage differentiation associated 2,7,4905989-4959213,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,83,cerebral cortex: 41.2;testis: 12.4,adrenal gland: 0.3,Not detected,,
2,NXPH1,,ENSG00000122584,Neurexophilin 1,7,8433955-8752963,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA020062,Uncertain,,,,,Group enriched,Group enriched,81,adrenal gland: 52.1;cerebral cortex: 47.2,breast: 0.6,Cell line enhanced,,Karpas-707: 7.7;SCLC-21H: 1.3;WM-115: 3.3
3,MCHR2,"GPR145, MCH2, MCH2R, SLT",ENSG00000152034,Melanin concentrating hormone receptor 2,6,99919910-99994247,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,47,cerebral cortex: 8.6;testis: 4.3,"colon,small intestine: 0.1",Not detected,,
4,POU3F3,"BRN1, OTF8",ENSG00000198914,POU class 3 homeobox 3,2,104855511-104858574,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052792, HPA056039, HPA067151",Approved,,Enhanced,Nucleus,Endometrial cancer:4.26e-5 (unfavourable),Group enriched,Group enriched,45,cerebral cortex: 43.9;epididymis: 46.3;kidney: 36.6;seminal vesicle: 23.2,skin: 0.8,Group enriched,5.0,AF22: 58.4;AN3-CA: 52.7;HEK93: 20.3;RPTEC TERT1: 50.7;SH-SY5Y: 19.7
5,ZIC5,,ENSG00000139800,Zic family member 5,13,99962964-99971909,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA074045,,,Uncertain,Nucleoplasm<br>Vesicles,,Mixed,Group enriched,45,cerebral cortex: 2.3;testis: 6.6,all non-specific tissues: 0.0,Cell line enhanced,,AF22: 21.7;NTERA-2: 15.0;SCLC-21H: 100.6
6,KIAA1549L,"C11orf41, C11orf69, G2, MGC34830",ENSG00000110427,KIAA1549 like,11,33542072-33674102,Predicted membrane proteins,Evidence at protein level,HPA051594,,,Approved,Nucleoplasm,,Mixed,Group enriched,41,cerebral cortex: 34.9;parathyroid gland: 146.2,skin: 2.2,Cell line enhanced,,TIME: 43.4;U-138 MG: 64.2;WM-115: 44.5
7,SCN1A,"FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI",ENSG00000144285,Sodium voltage-gated channel alpha subunit 1,2,165989160-166149214,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA078664,,,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane,,Tissue enriched,Group enriched,41,cerebral cortex: 10.3;fallopian tube: 2.9;lung: 2.2,"adrenal gland,placenta,testis: 0.1",Cell line enhanced,,AF22: 1.1;ASC TERT1: 4.4;Hep G2: 1.1
8,PHF24,KIAA1045,ENSG00000122733,PHD finger protein 24,9,34957608-34982544,Predicted intracellular proteins,Evidence at protein level,HPA020974,Approved,,,,,Tissue enhanced,Group enriched,36,cerebral cortex: 58.6;testis: 25.9,skin: 1.1,Cell line enhanced,,WM-115: 1.1
9,ELAVL2,"HEL-N1, HuB",ENSG00000107105,ELAV like RNA binding protein 2,9,23690104-23826337,Predicted intracellular proteins,Evidence at protein level,"CAB022222, HPA063001",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enhanced,Group enriched,32,cerebral cortex: 37.9;testis: 80.3,adrenal gland: 1.8,Cell line enhanced,,AF22: 36.8;SCLC-21H: 145.6
10,FRMPD4,"KIAA0316, PDZD10, PDZK10",ENSG00000169933,FERM and PDZ domain containing 4,X,12138466-12724523,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,31,cerebral cortex: 17.7;parathyroid gland: 30.1,heart muscle: 0.7,Cell line enhanced,,LHCN-M2: 3.5;U-2197: 6.0;U-266/70: 4.5
11,EGR4,"NGFI-C, PAT133",ENSG00000135625,Early growth response 4,2,73290929-73293705,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA028983,Enhanced,,,,,Mixed,Group enriched,29,cerebral cortex: 9.7;testis: 3.2,"adipose tissue,appendix: 0.2",Cell line enriched,6.0,HMC-1: 1.4
12,HIPK4,FLJ32818,ENSG00000160396,Homeodomain interacting protein kinase 4,19,40379271-40390187,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027733,Uncertain,,,,,Not detected,Group enriched,29,cerebral cortex: 4.7;testis: 14.6,endometrium: 0.3,Not detected,,
13,SOHLH1,"bA100C15.3, bHLHe80, C9orf157, NOHLH, SPATA27, TEB2",ENSG00000165643,Spermatogenesis and oogenesis specific basic helix-loop-helix 1,9,135693407-135699528,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059439,,,Approved,Nuclear speckles,,Mixed,Group enriched,27,cerebral cortex: 6.3;testis: 13.4,skin: 0.3,Group enriched,36.0,CACO-2: 14.6;U-266/84: 19.8
14,KCNJ4,"HIR, hIRK2, HRK1, IRK3, Kir2.3",ENSG00000168135,Potassium voltage-gated channel subfamily J member 4,22,38426327-38455199,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,25,cerebral cortex: 40.9;heart muscle: 11.4,gallbladder: 1.0,Cell line enriched,8.0,SCLC-21H: 13.4
15,NKX6-2,"GTX, NKX6.1, NKX6B",ENSG00000148826,NK6 homeobox 2,10,132783179-132786052,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,25,cerebral cortex: 15.7;stomach: 16.7,testis: 0.6,Not detected,,
16,SLC7A10,asc-1,ENSG00000130876,Solute carrier family 7 member 10,19,33208664-33225850,"Predicted membrane proteins, Transporters",Evidence at transcript level,"HPA041884, HPA057036",Uncertain,,Uncertain,Nucleus<br>Nucleoli,,Mixed,Group enriched,24,adipose tissue: 31.6;cerebral cortex: 6.5,breast: 0.8,Cell line enhanced,,BEWO: 1.8;HSkMC: 1.2;THP-1: 2.6;U-2 OS: 1.1
17,UNC5A,"KIAA1976, UNC5H1",ENSG00000113763,Unc-5 netrin receptor A,5,176810477-176880895,Predicted membrane proteins,Evidence at protein level,HPA071450,,,Approved,Plasma membrane<br>Cytosol,Endometrial cancer:2.23e-4 (unfavourable),Tissue enhanced,Group enriched,22,adrenal gland: 10.3;cerebral cortex: 35.4,lymph node: 1.0,Cell line enriched,14.0,SCLC-21H: 104.8
18,CDH10,,ENSG00000040731,Cadherin 10,5,24487100-24644978,Predicted membrane proteins,Evidence at protein level,HPA010651,Approved,,,,,Group enriched,Group enriched,20,cerebral cortex: 32.6;prostate: 7.5,adrenal gland: 1.0,Cell line enhanced,,AF22: 7.0;HAP1: 4.8;U-138 MG: 1.5
19,PNMA5,KIAA1934,ENSG00000198883,Paraneoplastic Ma antigen family member 5,X,152988824-152994127,Predicted intracellular proteins,Evidence at protein level,HPA044690,Enhanced,,,,"Colorectal cancer:2.25e-4 (unfavourable), Lung cancer:3.16e-4 (favourable)",Mixed,Group enriched,20,cerebral cortex: 8.1;testis: 16.3,"skin,spleen: 0.5",Group enriched,495.0,HMC-1: 311.7;U-266/70: 426.0;U-266/84: 249.2
20,FNDC9,"C5orf40, MGC27121",ENSG00000172568,Fibronectin type III domain containing 9,5,157341600-157345721,Predicted membrane proteins,Evidence at transcript level,"HPA011115, HPA017291",Approved,,,,,Tissue enriched,Group enriched,18,adrenal gland: 6.2;cerebral cortex: 20.7,appendix: 0.7,Not detected,,
21,NPY,PYY4,ENSG00000122585,Neuropeptide Y,7,24284163-24291865,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016733, CAB034368, HPA036636, HPA044572, HPA056798",Supported,Supported,Enhanced,Golgi apparatus,Endometrial cancer:5.78e-4 (unfavourable),Tissue enriched,Group enriched,18,adrenal gland: 153.2;cerebral cortex: 211.6;prostate: 495.0,appendix: 16.1,Cell line enriched,39.0,SH-SY5Y: 696.9
22,LYPD1,"LYPDC1, MGC29643",ENSG00000150551,LY6/PLAUR domain containing 1,2,132644853-132671579,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,17,cerebral cortex: 27.2;fallopian tube: 127.3,salivary gland: 4.5,Cell line enhanced,,hTEC/SVTERT24-B: 56.7;U-251 MG: 88.0;WM-115: 207.2
23,RAB3C,,ENSG00000152932,"RAB3C, member RAS oncogene family",5,58582221-58859394,Predicted intracellular proteins,Evidence at protein level,"HPA003160, HPA048156",Enhanced,,Approved,Cytosol,,Mixed,Group enriched,17,adrenal gland: 12.0;cerebral cortex: 55.3,small intestine: 2.0,Cell line enhanced,,HEL: 2.2;SCLC-21H: 11.9;SH-SY5Y: 3.9
24,AQP4,MIWC,ENSG00000171885,Aquaporin 4,18,26852038-26865818,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB005079, HPA014784, CAB058689",Enhanced,Supported,Supported,Plasma membrane<br>Cell Junctions,,Tissue enriched,Group enriched,16,cerebral cortex: 630.0;lung: 171.9,thyroid gland: 24.4,Cell line enhanced,,AF22: 2.4;RPTEC TERT1: 1.0
25,ELMOD1,DKFZp547C176,ENSG00000110675,ELMO domain containing 1,11,107591091-107666779,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038434, HPA038435",,,Supported,Nucleoplasm<br>Cytosol,,Tissue enriched,Group enriched,15,cerebral cortex: 71.3;skin: 36.7,"adrenal gland,fallopian tube: 3.5",Cell line enhanced,,HUVEC TERT2: 12.8;RH-30: 33.5
26,MDGA2,MAMDC1,ENSG00000139915,MAM domain containing glycosylphosphatidylinositol anchor 2,14,46839629-47674954,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA003084,Uncertain,,,,,Tissue enhanced,Group enriched,15,cerebral cortex: 6.2;testis: 6.9,skin: 0.4,Cell line enhanced,,AF22: 5.0;T-47d: 2.4;U-138 MG: 5.6;U-2 OS: 4.3;WM-115: 3.4
27,UNC13C,"DKFZp547H074, Munc13-3",ENSG00000137766,Unc-13 homolog C,15,54012904-54633414,Predicted intracellular proteins,Evidence at protein level,HPA041516,Uncertain,,,,,Not detected,Group enriched,15,cerebral cortex: 17.4;testis: 15.3,"ovary,thyroid gland: 1.1",Group enriched,9.0,Karpas-707: 52.9;U-266/70: 74.2
28,DISP3,"KIAA1337, PTCHD2",ENSG00000204624,Dispatched RND transporter family member 3,1,11479166-11537584,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA054579,Uncertain,,Uncertain,Nucleoplasm<br>Cytosol,,Tissue enhanced,Group enriched,14,cerebral cortex: 8.6;testis: 4.3,"adrenal gland,prostate: 0.4",Cell line enhanced,,AF22: 4.8;NTERA-2: 2.1;SCLC-21H: 2.3;SH-SY5Y: 7.2
29,RASGRF1,"CDC25, CDC25L, GNRP, GRF1, GRF55, H-GRF55, PP13187",ENSG00000058335,Ras protein specific guanine nucleotide releasing factor 1,15,78959947-79090773,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010413, HPA041965",Approved,,Supported,Golgi apparatus,Endometrial cancer:6.14e-6 (favourable),Mixed,Group enriched,14,cerebral cortex: 30.5;lung: 11.3,lymph node: 1.5,Cell line enhanced,,A-431: 7.3;BEWO: 7.5;Karpas-707: 7.5;RPMI-8226: 9.0;U-2 OS: 15.8
30,CALY,"CALCYON, DRD1IP, NSG3",ENSG00000130643,Calcyon neuron specific vesicular protein,10,133324072-133336935,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA042283,Enhanced,,,,Pancreatic cancer:3.54e-4 (favourable),Group enriched,Group enriched,13,adrenal gland: 23.5;cerebral cortex: 77.1,testis: 3.8,Not detected,,
31,CCKBR,,ENSG00000110148,Cholecystokinin B receptor,11,6259736-6272127,"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,13,cerebral cortex: 13.6;pancreas: 5.4;stomach: 16.4,prostate: 0.9,Cell line enriched,8.0,NTERA-2: 69.8
32,CERS1,"LAG1, LASS1, UOG1",ENSG00000223802,Ceramide synthase 1,19,18868545-18896727,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045724,Approved,,Approved,Endoplasmic reticulum,,Tissue enhanced,Group enriched,13,cerebral cortex: 136.3;testis: 28.0,skeletal muscle: 6.5,Cell line enhanced,,AN3-CA: 28.0;HEK93: 28.4
33,FABP7,"B-FABP, BLBP",ENSG00000164434,Fatty acid binding protein 7,6,122779475-122784074,Predicted intracellular proteins,Evidence at protein level,"CAB025488, HPA028825, CAB058697",Enhanced,,,,"Renal cancer:1.65e-6 (unfavourable), Breast cancer:2.49e-4 (favourable)",Group enriched,Group enriched,13,breast: 33.1;cerebral cortex: 102.3,skin: 5.2,Group enriched,8.0,AF22: 75.1;U-251 MG: 17.6;WM-115: 45.7
34,GPR22,,ENSG00000172209,G protein-coupled receptor 22,7,107470018-107475659,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Group enriched,13,"adrenal gland: 1.2;cerebral cortex: 4.7;cervix, uterine: 3.2;endometrium: 2.5;heart muscle: 5.4",smooth muscle: 0.2,Cell line enriched,29.0,SH-SY5Y: 2.9
35,GSG1L2,,ENSG00000214978,GSG1 like 2,17,9802386-9822071,Predicted membrane proteins,Evidence at transcript level,HPA059428,Uncertain,,,,,Tissue enriched,Group enriched,13,cerebral cortex: 1.5;testis: 1.0,all non-specific tissues: 0.0,Not detected,,
36,PNMA3,"MA3, MA5, MGC132756, MGC132758",ENSG00000183837,Paraneoplastic Ma antigen 3,X,153056409-153060467,Predicted intracellular proteins,Evidence at transcript level,HPA047920,Approved,,,,Endometrial cancer:4.14e-5 (unfavourable),Mixed,Group enriched,13,cerebral cortex: 15.4;epididymis: 45.4;testis: 12.3,fallopian tube: 1.8,Cell line enhanced,,NTERA-2: 3.2;SCLC-21H: 1.2
37,C10orf90,"bA422P15.2, FATS, FLJ32938",ENSG00000154493,Chromosome 10 open reading frame 90,10,126424997-126670446,Predicted intracellular proteins,Evidence at protein level,"HPA038648, HPA057599",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Tissue enriched,Group enriched,12,breast: 5.6;cerebral cortex: 15.3;salivary gland: 4.3;testis: 12.1,"adipose tissue,skin: 0.7",Group enriched,9.0,SK-MEL-30: 94.3;U-2197: 33.5;U-266/84: 18.9;U-87 MG: 36.2;WM-115: 29.4
38,CNDP1,"CN1, CPGL2, HsT2308, MGC10825",ENSG00000150656,Carnosine dipeptidase 1,18,74534440-74587212,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008933,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 101.7;liver: 23.0,duodenum: 5.1,Cell line enriched,68.0,U-266/84: 57.1
39,CTNNA2,"CAP-R, CT114",ENSG00000066032,Catenin alpha 2,2,79185231-80648861,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB037175,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 111.6;epididymis: 81.5;testis: 32.2,adrenal gland: 6.3,Cell line enhanced,,AF22: 7.0;Karpas-707: 5.9;NTERA-2: 6.7;SCLC-21H: 4.5;SH-SY5Y: 11.4
40,DDX25,GRTH,ENSG00000109832,DEAD-box helicase 25,11,125903348-125943702,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA020137,Enhanced,,,,,Tissue enhanced,Group enriched,12,cerebral cortex: 34.6;testis: 163.8,thyroid gland: 8.0,Cell line enhanced,,NTERA-2: 10.8;SCLC-21H: 10.2
41,DLGAP3,"DAP3, SAPAP3",ENSG00000116544,DLG associated protein 3,1,34865436-34929585,Predicted intracellular proteins,Evidence at protein level,HPA026445,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 21.9;testis: 5.7,spleen: 1.1,Cell line enhanced,,Daudi: 5.7;NTERA-2: 4.2;SCLC-21H: 14.7
42,FAM57B,DKFZP434I2117,ENSG00000149926,Family with sequence similarity 57 member B,16,30024427-30052978,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030837,Uncertain,,,,,Tissue enriched,Group enriched,12,cerebral cortex: 18.6;testis: 77.0,skeletal muscle: 3.9,Cell line enhanced,,NTERA-2: 16.7;SCLC-21H: 105.0;SH-SY5Y: 35.9
43,FSD1,"MGC3213, MIR1",ENSG00000105255,Fibronectin type III and SPRY domain containing 1,19,4304600-4323843,Predicted intracellular proteins,Evidence at protein level,HPA043141,Supported,,,,Endometrial cancer:1.61e-4 (unfavourable),Group enriched,Group enriched,12,cerebral cortex: 25.4;testis: 9.1,lymph node: 1.4,Cell line enhanced,,SCLC-21H: 65.0;SH-SY5Y: 60.9
44,FUT9,Fuc-TIX,ENSG00000172461,Fucosyltransferase 9,6,96015984-96215612,Predicted membrane proteins,Evidence at protein level,HPA070923,,,Approved,Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Cytosol,,Tissue enhanced,Group enriched,12,cerebral cortex: 28.1;stomach: 22.4,duodenum: 2.0,Cell line enhanced,,MCF7: 2.2;RT4: 5.1;SCLC-21H: 7.5;SK-BR-3: 2.7
45,SH3GL3,"CNSA3, EEN-B2, HsT19371, SH3D2C, SH3P13",ENSG00000140600,"SH3 domain containing GRB2 like 3, endophilin A3",15,83447228-83618743,Predicted intracellular proteins,Evidence at protein level,HPA039381,Enhanced,,,,,Mixed,Group enriched,12,cerebral cortex: 29.9;testis: 38.5,lung: 2.9,Cell line enhanced,,HAP1: 30.3;HEK93: 13.3;K-562: 21.4;RH-30: 8.7
46,SLC30A3,ZNT3,ENSG00000115194,Solute carrier family 30 member 3,2,27253684-27275817,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA060505, HPA067637, CAB079044",Enhanced,Approved,Approved,Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol,,Mixed,Group enriched,12,cerebral cortex: 36.6;epididymis: 55.4;testis: 43.5,heart muscle: 3.6,Cell line enhanced,,HAP1: 10.6;Hep G2: 9.5;REH: 20.7;RH-30: 11.0
47,ZIC3,"HTX, HTX1, ZNF203",ENSG00000156925,Zic family member 3,X,137566142-137577691,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052936, HPA069523",Approved,,Supported,Nucleoplasm,,Tissue enriched,Group enriched,12,cerebral cortex: 1.6;testis: 1.3,"bone marrow,skin: 0.1",Group enriched,38.0,AF22: 39.4;NTERA-2: 44.7
48,CARNS1,"ATPGD1, KIAA1394",ENSG00000172508,Carnosine synthase 1,11,67414968-67425607,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA038569,Enhanced,,,,,Group enriched,Group enriched,11,cerebral cortex: 37.1;skeletal muscle: 25.9,heart muscle: 2.9,Cell line enriched,10.0,RPMI-8226: 5.3
49,CNTNAP2,"Caspr2, KIAA0868, NRXN4",ENSG00000174469,Contactin associated protein-like 2,7,146116002-148420998,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA002739,Enhanced,,,,,Tissue enhanced,Group enriched,11,cerebral cortex: 17.9;prostate: 6.0,fallopian tube: 1.0,Cell line enhanced,,AF22: 7.9;CACO-2: 5.7;NTERA-2: 11.9;SCLC-21H: 28.5
50,DGKI,DGK-IOTA,ENSG00000157680,Diacylglycerol kinase iota,7,137381037-137847092,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA021924,,,Approved,Nucleoplasm,,Mixed,Group enriched,11,cerebral cortex: 9.3;thyroid gland: 33.0,"heart muscle,smooth muscle: 1.8",Cell line enhanced,,SCLC-21H: 7.5;U-2197: 16.4;U-87 MG: 6.3
51,FSTL5,"DKFZp566D234, KIAA1263",ENSG00000168843,Follistatin like 5,4,161383897-162164035,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enriched,Group enriched,11,adrenal gland: 7.8;cerebral cortex: 16.2,testis: 1.1,Cell line enhanced,,HL-60: 9.8;HUVEC TERT2: 9.0;Karpas-707: 53.8;SH-SY5Y: 11.3;U-2197: 15.1
52,GPR88,,ENSG00000181656,G protein-coupled receptor 88,1,100538137-100542018,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at transcript level,HPA007488,,Approved,,,,Tissue enriched,Group enriched,11,breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4,prostate: 0.6,Group enriched,8.0,HSkMC: 1.1;SCLC-21H: 2.3
53,LRIT2,"AC022389.4, LRRC22",ENSG00000204033,"Leucine rich repeat, Ig-like and transmembrane domains 2",10,84220495-84225589,Predicted membrane proteins,Evidence at protein level,HPA037788,Supported,,,,,Not detected,Group enriched,11,cerebral cortex: 1.0;skin: 3.1,"colon,esophagus,small intestine,spleen,testis: 0.1",Not detected,,
54,MCF2,"ARHGEF21, DBL",ENSG00000101977,MCF.2 cell line derived transforming sequence,X,139581770-139708227,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,11,adrenal gland: 38.3;cerebral cortex: 8.7;epididymis: 15.0;ovary: 12.9;seminal vesicle: 24.0;testis: 34.6,prostate: 2.0,Cell line enriched,12.0,U-251 MG: 30.6
55,PLPPR5,"LPPR5, PAP2, PAP2D, PRG5",ENSG00000117598,Phospholipid phosphatase related 5,1,98890245-99005032,Predicted membrane proteins,Evidence at transcript level,"HPA018072, HPA059085",Uncertain,,Approved,Plasma membrane<br>Cytosol,Renal cancer:6.22e-4 (unfavourable),Group enriched,Group enriched,11,cerebral cortex: 12.0;testis: 4.0,adrenal gland: 0.7,Group enriched,7.0,PC-3: 12.4;SH-SY5Y: 25.0
56,ADD2,ADDB,ENSG00000075340,Adducin 2,2,70607618-70768225,Predicted intracellular proteins,Evidence at protein level,"CAB009796, HPA034509, HPA034510",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Group enriched,10,bone marrow: 40.2;cerebral cortex: 44.7,testis: 4.2,Cell line enhanced,,K-562: 41.5;NTERA-2: 86.7;SCLC-21H: 50.4;U-251 MG: 38.9
57,BRINP2,"DBCCR1L2, FAM5B",ENSG00000198797,BMP/retinoic acid inducible neural specific 2,1,177171497-177282422,"Predicted secreted proteins, Transporters",Evidence at transcript level,"HPA050681, HPA061920",Uncertain,,Approved,Nucleoli<br>Vesicles,,Tissue enriched,Group enriched,10,adrenal gland: 11.5;cerebral cortex: 35.4,testis: 2.3,Group enriched,5.0,HDLM-2: 6.7;PC-3: 1.6;REH: 1.8;SCLC-21H: 7.3;SH-SY5Y: 1.4
58,CRB1,"LCA8, RP12",ENSG00000134376,"Crumbs 1, cell polarity complex component",1,197268204-197478455,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA061250, HPA063127",Approved,,Uncertain,Vesicles,,Tissue enriched,Group enriched,10,cerebral cortex: 12.2;testis: 5.0,ovary: 0.8,Cell line enriched,5.0,HeLa: 9.0
59,DDN,KIAA0749,ENSG00000181418,Dendrin,12,48995149-48999309,Predicted intracellular proteins,Evidence at protein level,HPA060952,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,10,cerebral cortex: 96.0;skeletal muscle: 46.6,kidney: 6.9,Cell line enhanced,,HAP1: 12.6;RPMI-8226: 16.5;SCLC-21H: 14.1
60,DLGAP2,DAP-2,ENSG00000198010,DLG associated protein 2,8,737596-1708474,"Nuclear receptors, Predicted intracellular proteins",Evidence at protein level,HPA030320,Uncertain,,,,,Not detected,Group enriched,10,cerebral cortex: 2.0;testis: 6.1,thyroid gland: 0.4,Not detected,,
61,GLRA2,GLR,ENSG00000101958,Glycine receptor alpha 2,X,14529298-14731812,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,CAB070422,Approved,,,,,Mixed,Group enriched,10,cerebral cortex: 6.1;colon: 1.4;rectum: 4.3,testis: 0.3,Cell line enriched,41.0,AN3-CA: 16.1
62,HTR1A,"5-HT1A, ADRB2RL1, ADRBRL1",ENSG00000178394,5-hydroxytryptamine receptor 1A,5,63960356-63962507,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018073,Uncertain,,,,,Not detected,Group enriched,10,cerebral cortex: 1.9;ovary: 3.9,testis: 0.2,Group enriched,16.0,NTERA-2: 1.6;SCLC-21H: 1.5
63,KCTD4,bA321C24.3,ENSG00000180332,Potassium channel tetramerization domain containing 4,13,45192853-45194717,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040734,Uncertain,,Approved,Microtubule organizing center,,Group enriched,Group enriched,10,cerebral cortex: 17.7;skin: 3.7,gallbladder: 1.1,Cell line enhanced,,RPTEC TERT1: 8.8;U-138 MG: 13.7;U-87 MG: 27.1
64,MC4R,,ENSG00000166603,Melanocortin 4 receptor,18,60371110-60372775,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA016719,Uncertain,,,,,Tissue enhanced,Group enriched,10,cerebral cortex: 2.9;fallopian tube: 5.0,epididymis: 0.4,Cell line enriched,64.0,fHDF/TERT166: 75.8
65,SRRM3,FLJ37078,ENSG00000177679,Serine/arginine repetitive matrix 3,7,76201900-76287288,Predicted intracellular proteins,Evidence at protein level,HPA019337,Uncertain,,Approved,Plasma membrane<br>Intermediate filaments<br>Microtubules,,Mixed,Group enriched,10,adrenal gland: 2.7;cerebral cortex: 8.5;testis: 1.8,stomach: 0.4,Group enriched,12.0,SCLC-21H: 12.8;SH-SY5Y: 8.5
66,CLEC2L,FLJ32986,ENSG00000236279,C-type lectin domain family 2 member L,7,139523856-139544984,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045050,Enhanced,,,,,Mixed,Group enriched,9,cerebral cortex: 21.0;parathyroid gland: 13.7,endometrium: 1.9,Cell line enhanced,,NTERA-2: 1.3;U-266/70: 2.4;U-266/84: 8.8
67,DOC2A,,ENSG00000149927,Double C2 domain alpha,16,30005509-30023270,Predicted intracellular proteins,Evidence at protein level,HPA065676,,,Uncertain,Nucleus<br>Nucleoli<br>Cell Junctions,,Tissue enhanced,Group enriched,9,cerebral cortex: 69.7;testis: 21.0,ovary: 5.2,Cell line enhanced,,BEWO: 12.9;SCLC-21H: 42.7;U-937: 14.1
68,ELAVL4,"HUD, PNEM",ENSG00000162374,ELAV like RNA binding protein 4,1,50048014-50203786,Predicted intracellular proteins,Evidence at protein level,"CAB004442, HPA043047",Enhanced,,Approved,Nucleoplasm<br>Vesicles,,Group enriched,Group enriched,9,adrenal gland: 10.7;cerebral cortex: 53.3;testis: 10.9,appendix: 2.9,Cell line enriched,21.0,SH-SY5Y: 131.1
69,HRK,DP5,ENSG00000135116,"Harakiri, BCL2 interacting protein",12,116856144-116881441,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB025973,Uncertain,,,,,Mixed,Group enriched,9,cerebral cortex: 13.3;thyroid gland: 6.4,testis: 1.1,Cell line enhanced,,Daudi: 7.9;SCLC-21H: 10.7;SH-SY5Y: 8.3;SK-MEL-30: 16.7;U-698: 25.7
70,KCNIP2,KCHIP2,ENSG00000120049,Potassium voltage-gated channel interacting protein 2,10,101825974-101843920,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,9,adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2,breast: 16.6,Cell line enhanced,,HEL: 13.8;HMC-1: 9.2
71,KIAA1107,,ENSG00000069712,KIAA1107,1,92166985-92184723,Predicted intracellular proteins,Evidence at protein level,HPA024216,Supported,,,,,Mixed,Group enriched,9,cerebral cortex: 45.9;testis: 10.7,"adrenal gland,epididymis: 3.2",Mixed,,
72,NXPH2,NPH2,ENSG00000144227,Neurexophilin 2,2,138670772-138780348,Predicted secreted proteins,Evidence at transcript level,HPA034759,Approved,,,,,Mixed,Group enriched,9,cerebral cortex: 5.7;kidney: 5.0;ovary: 14.0,endometrium: 0.9,Cell line enhanced,,AF22: 3.8;SCLC-21H: 1.7;SiHa: 4.0;U-2 OS: 6.3;U-251 MG: 1.7
73,PEX5L,"PEX5R, PXR2, TRIP8b",ENSG00000114757,Peroxisomal biogenesis factor 5 like,3,179794958-180037053,Predicted intracellular proteins,Evidence at protein level,HPA058026,Enhanced,,,,,Tissue enhanced,Group enriched,9,cerebral cortex: 67.5;parathyroid gland: 94.8,testis: 8.6,Group enriched,5.0,HDLM-2: 7.2;MOLT-4: 22.2;RPMI-8226: 15.1;SCLC-21H: 15.0;U-266/70: 12.8
74,SCN2B,,ENSG00000149575,Sodium voltage-gated channel beta subunit 2,11,118161951-118176673,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Group enriched,9,cerebral cortex: 34.7;heart muscle: 7.1,smooth muscle: 2.4,Cell line enhanced,,U-2197: 1.6
75,TMEM130,"DKFZp761L1417, FLJ42643",ENSG00000166448,Transmembrane protein 130,7,98846488-98870771,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012928,Uncertain,,Supported,Golgi apparatus,Lung cancer:7.84e-4 (favourable),Tissue enhanced,Group enriched,9,adrenal gland: 49.1;cerebral cortex: 183.0;testis: 70.7,epididymis: 11.5,Cell line enhanced,,BJ hTERT+: 5.4;EFO-21: 6.0;NTERA-2: 3.8;SH-SY5Y: 8.3
76,ZFR2,KIAA1086,ENSG00000105278,Zinc finger RNA binding protein 2,19,3804024-3869032,Predicted intracellular proteins,Evidence at protein level,"HPA043275, HPA055678",Uncertain,,Uncertain,Nucleoplasm,,Tissue enhanced,Group enriched,9,adrenal gland: 3.8;cerebral cortex: 12.7;testis: 19.0,fallopian tube: 1.3,Group enriched,12.0,HMC-1: 24.1;NTERA-2: 47.6;SiHa: 15.2
77,ADCY8,"AC8, ADCY3, HBAC1",ENSG00000155897,Adenylate cyclase 8,8,130780301-131042426,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB018652, HPA024291",Supported,,,,,Group enriched,Group enriched,8,cerebral cortex: 12.9;epididymis: 27.8;fallopian tube: 6.2,seminal vesicle: 2.0,Group enriched,7.0,U-138 MG: 17.5;U-87 MG: 33.7
78,ASCL1,"ASH1, bHLHa46, HASH1",ENSG00000139352,Achaete-scute family bHLH transcription factor 1,12,102957686-102960516,"Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA029217,Enhanced,,,,,Group enriched,Group enriched,8,cerebral cortex: 16.2;liver: 6.4,adrenal gland: 1.4,Group enriched,23.0,SCLC-21H: 63.4;SH-SY5Y: 30.9
79,ATP2B3,"CFAP39, CLA2, PMCA3, SCAX1",ENSG00000067842,ATPase plasma membrane Ca2+ transporting 3,X,153517676-153582939,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA001583,Enhanced,,Uncertain,Golgi apparatus<br>Plasma membrane,,Not detected,Group enriched,8,adrenal gland: 12.1;cerebral cortex: 19.0,fallopian tube: 2.0,Cell line enhanced,,SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9
80,CACNA1B,"CACNL1A5, CACNN, Cav2.2",ENSG00000148408,Calcium voltage-gated channel subunit alpha1 B,9,137877789-138124624,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA044347,Uncertain,,,,,Tissue enhanced,Group enriched,8,adrenal gland: 3.7;cerebral cortex: 14.8;fallopian tube: 4.9;testis: 7.6,prostate: 0.9,Cell line enriched,6.0,SCLC-21H: 23.0
81,CADPS,"CAPS, CAPS1, KIAA1121, UNC-31",ENSG00000163618,Calcium dependent secretion activator,3,62398346-62875389,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA059328,Enhanced,,Approved,Vesicles,,Mixed,Group enriched,8,adrenal gland: 21.6;cerebral cortex: 94.1,heart muscle: 7.5,Cell line enhanced,,SCLC-21H: 23.2;SK-MEL-30: 7.0;U-698: 8.9;U-87 MG: 20.1
82,CDH8,,ENSG00000150394,Cadherin 8,16,61647242-62037035,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014908,Approved,,,,,Tissue enhanced,Group enriched,8,cerebral cortex: 27.8;seminal vesicle: 6.9,ovary: 2.1,Cell line enhanced,,AF22: 6.9;fHDF/TERT166: 4.9;HaCaT: 12.6;LHCN-M2: 14.1
83,CHRM1,,ENSG00000168539,Cholinergic receptor muscarinic 1,11,62908679-62921807,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA014101, CAB022366",Enhanced,,Approved,Nucleus<br>Cytosol,,Tissue enriched,Group enriched,8,cerebral cortex: 39.9;prostate: 42.3;salivary gland: 11.0,adrenal gland: 3.8,Cell line enhanced,,MCF7: 2.7;SK-BR-3: 1.2;T-47d: 1.0
84,CTXN2,,ENSG00000233932,Cortexin 2,15,48191539-48203756,Predicted membrane proteins,Evidence at transcript level,HPA053168,Uncertain,,,,,Not detected,Group enriched,8,cerebral cortex: 1.9;testis: 1.5,fallopian tube: 0.2,Not detected,,
85,DACH2,,ENSG00000126733,Dachshund family transcription factor 2,X,86148458-86832604,Predicted intracellular proteins,Evidence at transcript level,HPA000258,Approved,,,,,Not detected,Group enriched,8,cerebral cortex: 11.9;epididymis: 4.4;fallopian tube: 5.0,kidney: 0.8,Cell line enriched,8.0,HAP1: 6.1
86,DPYSL5,"CRAM, CRMP-5, CRMP5, Ulip6",ENSG00000157851,Dihydropyrimidinase like 5,2,26847747-26950351,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034544, HPA072387",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Group enriched,Group enriched,8,cerebral cortex: 31.3;testis: 10.0,adrenal gland: 2.5,Cell line enhanced,,AF22: 139.1;HAP1: 122.4;SCLC-21H: 196.8;SH-SY5Y: 105.0
87,ETNPPL,AGXT2L1,ENSG00000164089,Ethanolamine-phosphate phospho-lyase,4,108742040-108763054,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA044546, HPA072938",Approved,,Approved,Nucleus,Glioma:1.31e-4 (favourable),Group enriched,Group enriched,8,cerebral cortex: 141.2;liver: 98.6,stomach: 15.2,Cell line enhanced,,HeLa: 3.8;Hep G2: 1.5;NTERA-2: 1.1
88,FAM135B,C8ORFK32,ENSG00000147724,Family with sequence similarity 135 member B,8,138130023-138496822,Predicted intracellular proteins,Evidence at transcript level,"HPA023911, HPA023950, HPA024815",Uncertain,,Approved,Nucleoplasm<br>Nuclear membrane,,Tissue enhanced,Group enriched,8,adrenal gland: 3.6;cerebral cortex: 8.3;testis: 7.3,colon: 0.8,Cell line enriched,11.0,RH-30: 8.5
89,HBQ1,HBQ,ENSG00000086506,Hemoglobin subunit theta 1,16,180453-181181,Predicted intracellular proteins,Evidence at protein level,HPA062473,Enhanced,,Approved,Lipid droplets,,Mixed,Group enriched,8,bone marrow: 14.7;cerebral cortex: 3.0,placenta: 1.1,Group enriched,7.0,HEL: 19.6;Hep G2: 10.4;K-562: 49.1
90,KCNMB4,,ENSG00000135643,Potassium calcium-activated channel subfamily M regulatory beta subunit 4,12,70366276-70434292,Predicted membrane proteins,Evidence at protein level,HPA072287,Enhanced,,Approved,Cytosol,,Mixed,Group enriched,8,adrenal gland: 19.5;cerebral cortex: 38.1,placenta: 3.7,Cell line enhanced,,NTERA-2: 7.7;RH-30: 8.0;RT4: 7.4
91,MCF2L2,"ARHGEF22, KIAA0861",ENSG00000053524,MCF.2 cell line derived transforming sequence-like 2,3,183178043-183428778,"Disease related genes, Predicted intracellular proteins",Evidence at transcript level,"HPA038946, HPA038947",Uncertain,,Approved,Plasma membrane<br>Cytosol,,Not detected,Group enriched,8,adrenal gland: 10.2;cerebral cortex: 17.2;parathyroid gland: 7.7;spleen: 3.5;testis: 4.7,prostate: 1.0,Cell line enhanced,,HDLM-2: 5.5;Karpas-707: 3.6;REH: 3.1
92,NAT16,"C7orf52, FLJ39237",ENSG00000167011,N-acetyltransferase 16 (putative),7,101170493-101180276,Predicted intracellular proteins,Evidence at transcript level,HPA021918,Uncertain,,Approved,Nucleus,,Tissue enhanced,Group enriched,8,cerebral cortex: 5.1;thyroid gland: 3.0,pancreas: 0.5,Cell line enhanced,,RPMI-8226: 1.6;SH-SY5Y: 3.6;SK-MEL-30: 2.0;U-2 OS: 3.1;U-87 MG: 1.6
93,RASGEF1C,FLJ35841,ENSG00000146090,RasGEF domain family member 1C,5,180100791-180209153,Predicted intracellular proteins,Evidence at transcript level,HPA028242,Uncertain,,Approved,Mitochondria,,Tissue enhanced,Group enriched,8,cerebral cortex: 16.4;testis: 6.1,seminal vesicle: 1.3,Cell line enhanced,,BEWO: 2.2;MCF7: 1.9;SCLC-21H: 9.1;U-2 OS: 2.5
94,RGS7,,ENSG00000182901,Regulator of G-protein signaling 7,1,240775515-241357230,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB017561,Enhanced,,Enhanced,Cytosol,,Tissue enhanced,Group enriched,8,adrenal gland: 10.7;cerebral cortex: 46.4;testis: 10.9,stomach: 2.9,Cell line enhanced,,U-2 OS: 6.8
95,S100B,S100beta,ENSG00000160307,S100 calcium binding protein B,21,46598962-46605208,"Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB000073, HPA015768, CAB078196",Enhanced,,Approved,Nucleus<br>Vesicles,,Group enriched,Group enriched,8,adipose tissue: 208.2;cerebral cortex: 626.3,seminal vesicle: 49.5,Group enriched,6.0,SK-MEL-30: 519.7;WM-115: 1274.2
96,SCG2,"CHGC, SgII, SN",ENSG00000171951,Secretogranin II,2,223596940-223602503,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA011893, HPA075062",Enhanced,Supported,,,"Renal cancer:7.01e-10 (unfavourable), Pancreatic cancer:5.58e-4 (favourable)",Group enriched,Group enriched,8,adrenal gland: 446.7;cerebral cortex: 232.0,duodenum: 45.1,Cell line enhanced,,ASC TERT1: 35.0;HSkMC: 31.4;SCLC-21H: 52.8;SH-SY5Y: 20.7;WM-115: 32.8
97,SOX1,,ENSG00000182968,SRY-box 1,13,112067647-112070488,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Group enriched,Group enriched,8,cerebral cortex: 3.6;testis: 1.5,skin: 0.3,Group enriched,6.0,AF22: 44.0;SCLC-21H: 10.1
98,SYT16,"CHR14SYT, Strep14, SYT14L, yt14r",ENSG00000139973,Synaptotagmin 16,14,61811974-62112550,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA004199, HPA076871",Uncertain,,Approved,Cytosol,,Mixed,Group enriched,8,cerebral cortex: 18.0;prostate: 3.6;testis: 6.9,stomach: 1.2,Cell line enhanced,,A-431: 9.4;PC-3: 5.0;RPTEC TERT1: 4.7;RT4: 13.5;U-2 OS: 6.9
99,TMEM179,"C14orf90, FLJ42486, TMEM179A",ENSG00000258986,Transmembrane protein 179,14,104474678-104605647,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at transcript level,HPA002942,,,Uncertain,Mitochondria,,Mixed,Group enriched,8,adrenal gland: 14.6;cerebral cortex: 27.9,testis: 2.5,Cell line enhanced,,NTERA-2: 8.5;SCLC-21H: 42.8;SH-SY5Y: 12.2
100,ZMAT4,FLJ13842,ENSG00000165061,Zinc finger matrin-type 4,8,40530590-40897833,Predicted intracellular proteins,Evidence at protein level,"HPA056671, HPA069813",Enhanced,,Approved,Intermediate filaments,Thyroid cancer:3.51e-4 (unfavourable),Tissue enhanced,Group enriched,8,cerebral cortex: 10.1;thyroid gland: 27.6,testis: 2.4,Group enriched,5.0,AF22: 22.3;U-2197: 13.1
101,ARC,"Arg3.1, KIAA0278",ENSG00000198576,Activity regulated cytoskeleton associated protein,8,142611044-142614472,Predicted intracellular proteins,Evidence at protein level,"HPA056430, CAB079013",,Supported,Approved,Vesicles<br>Microtubules,,Tissue enriched,Group enriched,7,adipose tissue: 14.2;adrenal gland: 13.4;cerebral cortex: 14.4;gallbladder: 3.3;seminal vesicle: 5.5,placenta: 1.4,Cell line enhanced,,HEK93: 9.2;SCLC-21H: 27.7;U-2 OS: 11.9;U-87 MG: 12.5
102,BIN1,"AMPH2, AMPHL, SH3P9",ENSG00000136717,Bridging integrator 1,2,127048027-127107355,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB001945, HPA003894, HPA005437",Enhanced,,Supported,Cytosol,,Expressed in all,Group enriched,7,cerebral cortex: 156.4;skeletal muscle: 724.1,adrenal gland: 61.4,Mixed,,
103,C9orf129,bA165J3.3,ENSG00000204352,Chromosome 9 open reading frame 129,9,93318199-93346414,Predicted intracellular proteins,Evidence at transcript level,HPA071515,,,Uncertain,Mitochondria,,Not detected,Group enriched,7,cerebral cortex: 4.1;testis: 1.7,epididymis: 0.4,Cell line enriched,9.0,NTERA-2: 2.1
104,CBLN2,,ENSG00000141668,Cerebellin 2 precursor,18,72536680-72638521,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,7,cerebral cortex: 30.2;seminal vesicle: 7.3,small intestine: 2.8,Cell line enriched,8.0,SH-SY5Y: 57.5
105,CDR1,"CDR, CDR34, CDR62A",ENSG00000184258,Cerebellar degeneration related protein 1,X,140782405-140784871,Predicted intracellular proteins,Evidence at protein level,HPA073147,,,Approved,Nucleoplasm<br>Golgi apparatus<br>Centrosome,,Not detected,Group enriched,7,cerebral cortex: 48.4;skin: 12.1,adipose tissue: 4.0,Cell line enhanced,,BJ: 6.3;U-87 MG: 26.1
106,CECR6,,ENSG00000183307,"Cat eye syndrome chromosome region, candidate 6",22,17116299-17121367,Predicted membrane proteins,Evidence at protein level,HPA068790,Approved,,Approved,Nucleoplasm<br>Vesicles<br>Plasma membrane,,Tissue enhanced,Group enriched,7,cerebral cortex: 15.0;prostate: 10.8,testis: 1.9,Cell line enhanced,,AF22: 5.9;SCLC-21H: 16.7;THP-1: 8.0;U-937: 7.7
107,CHN1,"ARHGAP2, CHN, DURS2, n-chimerin, RhoGAP2",ENSG00000128656,Chimerin 1,2,174799363-175005369,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA036111,,,Approved,Cytosol,Renal cancer:5.07e-4 (unfavourable),Expressed in all,Group enriched,7,cerebral cortex: 639.0;parathyroid gland: 133.3,placenta: 56.0,Cell line enhanced,,BJ hTERT+: 172.5
108,CSMD3,,ENSG00000164796,CUB and Sushi multiple domains 3,8,112222928-113437099,Predicted membrane proteins,Evidence at transcript level,HPA029007,Uncertain,,,,,Not detected,Group enriched,7,cerebral cortex: 4.9;testis: 1.8,"fallopian tube,prostate,spleen: 0.4",Not detected,,
109,DNER,"bet, UNQ26",ENSG00000187957,Delta/notch like EGF repeat containing,2,229357629-229714558,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,HPA017320,Approved,,,,"Liver cancer:1.05e-4 (unfavourable), Renal cancer:3.42e-4 (unfavourable)",Tissue enriched,Group enriched,7,adrenal gland: 74.6;cerebral cortex: 176.0,salivary gland: 17.3,Cell line enhanced,,hTERT-HME1: 115.0;U-138 MG: 248.6;U-87 MG: 146.3
110,DPP10,"DPL2, DPPY, DPRP3",ENSG00000175497,Dipeptidyl peptidase like 10,2,114442299-115845752,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA048767,Uncertain,,Approved,Nucleus<br>Vesicles<br>Cytosol,,Mixed,Group enriched,7,adrenal gland: 14.1;cerebral cortex: 34.7,pancreas: 3.6,Cell line enhanced,,AF22: 4.1;HAP1: 6.4;HMC-1: 3.8;NTERA-2: 3.7;RT4: 5.3;SCLC-21H: 11.4;SH-SY5Y: 4.1
111,FAM216A,"C12orf24, HSU79274",ENSG00000204856,Family with sequence similarity 216 member A,12,110468364-110490385,Predicted intracellular proteins,Evidence at protein level,HPA038286,Enhanced,,Approved,Actin filaments,"Renal cancer:4.18e-10 (unfavourable), Liver cancer:4.49e-5 (unfavourable)",Expressed in all,Group enriched,7,cerebral cortex: 16.2;testis: 61.1,appendix: 5.5,Mixed,,
112,GALNT8,GALNAC-T8,ENSG00000130035,Polypeptide N-acetylgalactosaminyltransferase 8,12,4720341-4851927,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012638, HPA014418, HPA073461",Approved,,Approved,Vesicles,,Tissue enhanced,Group enriched,7,cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5,appendix: 3.2,Cell line enhanced,,Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
113,GOLGA7B,"bA451M19.3, bA459F3.4, C10orf132, C10orf133",ENSG00000155265,Golgin A7 family member B,10,97850239-97871580,Predicted intracellular proteins,Evidence at protein level,HPA046878,Uncertain,,,,,Mixed,Group enriched,7,cerebral cortex: 18.3;epididymis: 28.5;skin: 17.4,adrenal gland: 3.1,Cell line enhanced,,A-431: 4.7;HDLM-2: 5.4;SK-MEL-30: 17.6
114,HAPLN4,"BRAL2, KIAA1926",ENSG00000187664,Hyaluronan and proteoglycan link protein 4,19,19255641-19262796,Predicted secreted proteins,Evidence at protein level,HPA055856,Approved,,,,,Not detected,Group enriched,7,cerebral cortex: 8.4;duodenum: 15.3;small intestine: 21.2,"cervix, uterine: 2.1",Cell line enhanced,,NB-4: 2.6;NTERA-2: 10.4;SCLC-21H: 2.6
115,IGLON5,LOC402665,ENSG00000142549,IgLON family member 5,19,51311848-51330354,Predicted secreted proteins,Evidence at protein level,HPA041994,Approved,,Uncertain,Nucleus,Renal cancer:5.62e-7 (unfavourable),Tissue enhanced,Group enriched,7,adrenal gland: 2.3;cerebral cortex: 11.1;testis: 9.5,"esophagus,seminal vesicle: 1.0",Group enriched,8.0,HMC-1: 30.8;NTERA-2: 16.0;SH-SY5Y: 24.3;U-2 OS: 6.9
116,IL17D,"FLJ30846, IL-17D, IL-22, IL-27, IL27",ENSG00000172458,Interleukin 17D,13,20702127-20723098,Predicted secreted proteins,Evidence at protein level,,,,,,,Group enriched,Group enriched,7,cerebral cortex: 100.2;skeletal muscle: 45.9,ovary: 10.2,Mixed,,
117,KCNK9,"K2p9.1, TASK-3, TASK3",ENSG00000169427,Potassium two pore domain channel subfamily K member 9,8,139600838-139703056,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Mixed,Group enriched,7,adrenal gland: 4.7;cerebral cortex: 4.8,"cervix, uterine: 0.7",Cell line enhanced,,PC-3: 2.0;SCLC-21H: 1.1
118,KCTD16,KIAA1317,ENSG00000183775,Potassium channel tetramerization domain containing 16,5,144170832-144485686,Predicted intracellular proteins,Evidence at protein level,"HPA044590, HPA050154",Approved,,Approved,Nuclear speckles,,Tissue enhanced,Group enriched,7,cerebral cortex: 12.3;testis: 3.0,lung: 1.1,Cell line enhanced,,SCLC-21H: 5.4;TIME: 7.3
119,KHDRBS3,"Etle, etoile, SALP, SLM-2, SLM2, T-STAR",ENSG00000131773,"KH RNA binding domain containing, signal transduction associated 3",8,135457457-135656722,Predicted intracellular proteins,Evidence at protein level,"HPA000275, HPA000500, HPA000981",Enhanced,,Supported,Nucleoplasm,Renal cancer:7.16e-6 (favourable),Expressed in all,Group enriched,7,cerebral cortex: 89.1;testis: 285.9,epididymis: 27.8,Cell line enhanced,,WM-115: 83.8
120,LGI3,,ENSG00000168481,Leucine rich repeat LGI family member 3,8,22146825-22157084,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA024826,,,Approved,Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 76.0;lung: 23.9;skin: 17.3;thyroid gland: 21.6,esophagus: 5.2,Cell line enhanced,,A549: 1.0;SCLC-21H: 1.9;SK-MEL-30: 1.3;WM-115: 1.0
121,LRP8,"APOER2, HSZ75190, LRP-8, MCI1",ENSG00000157193,LDL receptor related protein 8,1,53242364-53328070,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA073031,Enhanced,,,,"Endometrial cancer:3.46e-6 (unfavourable), Lung cancer:7.02e-4 (unfavourable)",Mixed,Group enriched,7,cerebral cortex: 25.2;testis: 46.9;thyroid gland: 87.5,appendix: 7.7,Expressed in all,,
122,LRRC3B,LRP15,ENSG00000179796,Leucine rich repeat containing 3B,3,26622806-26710776,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA015568,Approved,,,,,Group enriched,Group enriched,7,cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0,"endometrium,ovary: 1.6",Cell line enhanced,,NTERA-2: 1.6
123,MAP6D1,"FLJ12748, SL21",ENSG00000180834,MAP6 domain containing 1,3,183815876-183825594,Predicted intracellular proteins,Evidence at protein level,HPA037991,Supported,,Approved,Cytosol,Prostate cancer:3.37e-4 (unfavourable),Mixed,Group enriched,7,cerebral cortex: 39.7;skeletal muscle: 10.3,skin: 3.6,Cell line enhanced,,T-47d: 66.1
124,MSANTD1,"C4orf44, LOC345222",ENSG00000188981,Myb/SANT DNA binding domain containing 1,4,3244369-3271738,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,7,cerebral cortex: 1.9;testis: 2.4,"epididymis,lung,spleen: 0.3",Not detected,,
125,MYT1,"MTF1, MYTI, NZF2, PLPB1, ZC2H2C1, ZC2HC4A",ENSG00000196132,Myelin transcription factor 1,20,64151791-64242253,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA006303,Uncertain,,Supported,Nucleoplasm<br>Cytosol,,Tissue enhanced,Group enriched,7,adrenal gland: 2.5;cerebral cortex: 5.7,testis: 0.6,Cell line enhanced,,REH: 3.3;SCLC-21H: 16.5;SH-SY5Y: 3.0
126,NAT8L,"FLJ37478, Hcml3",ENSG00000185818,N-acetyltransferase 8 like,4,2059512-2069089,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040677,,,Supported,Mitochondria,Endometrial cancer:1.01e-5 (unfavourable),Group enriched,Group enriched,7,adipose tissue: 48.6;cerebral cortex: 64.9;testis: 19.0,kidney: 6.7,Cell line enhanced,,SCLC-21H: 32.4
127,NOL4,"CT125, HRIHFB2255, NOLP",ENSG00000101746,Nucleolar protein 4,18,33851100-34224952,Predicted intracellular proteins,Evidence at protein level,HPA046740,,,Supported,Nucleus,,Tissue enhanced,Group enriched,7,cerebral cortex: 15.9;testis: 22.8,thyroid gland: 2.9,Cell line enhanced,,SCLC-21H: 44.1;SH-SY5Y: 10.6;U-698: 5.7
128,NWD1,,ENSG00000188039,NACHT and WD repeat domain containing 1,19,16719976-16817963,Predicted intracellular proteins,Evidence at protein level,,,,,,Endometrial cancer:2.55e-4 (favourable),Tissue enriched,Group enriched,7,cerebral cortex: 1.9;fallopian tube: 7.7;prostate: 5.8;seminal vesicle: 1.6,lung: 0.6,Group enriched,7.0,MCF7: 1.0;U-937: 2.3
129,OPRK1,"KOR, OPRK",ENSG00000082556,Opioid receptor kappa 1,8,53225716-53251697,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022595, HPA067549",Uncertain,,Supported,Nucleus<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 3.6;prostate: 2.8;testis: 1.3,"placenta,skeletal muscle: 0.3",Group enriched,7.0,AF22: 4.5;U-937: 17.3
130,PAX6,"AN, AN2, D11S812E, WAGR",ENSG00000007372,Paired box 6,11,31784779-31818062,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,"HPA030775, CAB034143",Supported,,Enhanced,Nucleoplasm,,Tissue enhanced,Group enriched,7,cerebral cortex: 22.3;stomach: 11.2,testis: 2.5,Cell line enhanced,,AF22: 15.6;AN3-CA: 19.1;HEK93: 17.3;U-251 MG: 14.4
131,PAX7,Hup1,ENSG00000009709,Paired box 7,1,18631006-18748866,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Group enriched,Group enriched,7,cerebral cortex: 1.3;skeletal muscle: 2.2,"esophagus,testis: 0.2",Group enriched,7.0,A549: 1.3;CAPAN-2: 1.4;U-2 OS: 3.5
132,PLEKHB1,"KPL1, PHR1, PHRET1",ENSG00000021300,Pleckstrin homology domain containing B1,11,73646178-73662819,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:1.99e-6 (favourable), Pancreatic cancer:6.02e-4 (favourable)",Expressed in all,Group enriched,7,cerebral cortex: 494.8;parathyroid gland: 148.4,thyroid gland: 48.4,Cell line enhanced,,EFO-21: 18.8;Hep G2: 52.2;U-266/84: 21.1
133,POPDC3,"bA355M14.1, MGC22671, POP3",ENSG00000132429,Popeye domain containing 3,6,105158280-105179995,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012514,,,Approved,Nucleoli<br>Cytosol,"Head and neck cancer:4.43e-4 (unfavourable), Lung cancer:5.79e-4 (unfavourable)",Mixed,Group enriched,7,cerebral cortex: 8.8;heart muscle: 19.8;skeletal muscle: 41.8;testis: 9.1,epididymis: 2.9,Cell line enhanced,,RH-30: 20.5
134,RP11-277P12.6,,ENSG00000255641,,12,10412312-10436001,Predicted membrane proteins,Evidence at transcript level,HPA062570,Uncertain,,,,,Not detected,Group enriched,7,cerebral cortex: 8.2;spleen: 6.1,bone marrow: 1.0,Cell line enriched,5.0,HeLa: 5.8
135,RS1,"RS, XLRS1",ENSG00000102104,Retinoschisin 1,X,18639910-18672109,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA059546,Supported,,,,,Not detected,Group enriched,7,cerebral cortex: 1.1;lung: 1.6,"lymph node,spleen,thyroid gland: 0.1",Not detected,,
136,SH2D5,,ENSG00000189410,SH2 domain containing 5,1,20719732-20732837,Predicted intracellular proteins,Evidence at protein level,HPA030182,,,Supported,Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 16.6;placenta: 5.1;testis: 9.9,thyroid gland: 1.5,Cell line enhanced,,HBEC3-KT: 34.9;hTERT-HME1: 46.6
137,SHC4,"RaLP, SHCD",ENSG00000185634,SHC adaptor protein 4,15,48823735-48963444,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA074146,,,Approved,Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 13.1;testis: 20.1,gallbladder: 2.3,Cell line enhanced,,AN3-CA: 9.5;SK-MEL-30: 15.2;WM-115: 16.3
138,SPHKAP,SKIP,ENSG00000153820,"SPHK1 interactor, AKAP domain containing",2,227979950-228181645,Predicted intracellular proteins,Evidence at protein level,"HPA042499, HPA048168",Enhanced,,,,,Not detected,Group enriched,7,cerebral cortex: 19.4;heart muscle: 19.0,ovary: 2.7,Cell line enriched,17.0,BJ hTERT+: 37.3
139,TCEAL5,WEX4,ENSG00000204065,Transcription elongation factor A like 5,X,103273691-103276872,Predicted intracellular proteins,Evidence at protein level,"HPA045564, HPA058982, HPA072199",Supported,,Uncertain,Nucleoplasm<br>Cytosol,"Pancreatic cancer:8.60e-4 (favourable), Endometrial cancer:9.09e-4 (unfavourable)",Tissue enhanced,Group enriched,7,cerebral cortex: 82.5;testis: 82.5,adrenal gland: 11.9,Group enriched,7.0,SCLC-21H: 9.3;SH-SY5Y: 25.9
140,ZIM2,ZNF656,ENSG00000269699,Zinc finger imprinted 2,19,56774552-56840729,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071856,,,Approved,Nuclear speckles<br>Cytosol,,Not detected,Group enriched,7,adrenal gland: 5.8;cerebral cortex: 5.1;ovary: 9.9;placenta: 6.8;testis: 7.7,endometrium: 1.0,Cell line enhanced,,BEWO: 4.7;Hep G2: 4.0;NTERA-2: 1.6;RH-30: 1.6;U-2 OS: 1.2
141,ZNF488,FLJ32104,ENSG00000265763,Zinc finger protein 488,10,47365496-47384273,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035957, HPA035958, HPA044867",Uncertain,,Supported,Nucleoplasm<br>Cytosol,Pancreatic cancer:4.02e-7 (unfavourable),Mixed,Group enriched,7,cerebral cortex: 19.0;duodenum: 22.6;placenta: 4.8;small intestine: 12.1,"epididymis,skin: 2.0",Cell line enhanced,,HaCaT: 41.7;HDLM-2: 65.3;RT4: 30.6
142,ABCG4,WHITE2,ENSG00000172350,ATP binding cassette subfamily G member 4,11,119149012-119162653,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA040312,Uncertain,,,,,Not detected,Group enriched,6,cerebral cortex: 6.6;parathyroid gland: 4.1;testis: 5.1,seminal vesicle: 0.8,Cell line enhanced,,AN3-CA: 1.7;HAP1: 1.0
143,ACP7,"FLJ16165, PAPL, PAPL1",ENSG00000183760,"Acid phosphatase 7, tartrate resistant (putative)",19,39083913-39111493,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA042005, HPA042613",Uncertain,,,,,Group enriched,Group enriched,6,cerebral cortex: 1.8;skin: 6.9;tonsil: 2.3,"epididymis,prostate: 0.5",Cell line enhanced,,hTEC/SVTERT24-B: 9.3;U-87 MG: 43.5
144,ACSL6,"ACS2, FACL6, KIAA0837, LACS2, LACS5",ENSG00000164398,Acyl-CoA synthetase long-chain family member 6,5,131949973-132012243,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040470,Enhanced,,,,,Group enriched,Group enriched,6,bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4,adrenal gland: 6.4,Group enriched,6.0,SCLC-21H: 13.0;U-937: 5.2
145,ADAM23,MDC3,ENSG00000114948,ADAM metallopeptidase domain 23,2,206443539-206621130,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA012130, CAB033276",Uncertain,,,,,Mixed,Group enriched,6,cerebral cortex: 55.4;parathyroid gland: 135.3,heart muscle: 16.5,Cell line enhanced,,RH-30: 61.7;RPMI-8226: 120.2
146,ANO4,"FLJ34221, FLJ34272, FLJ35277, TMEM16D",ENSG00000151572,Anoctamin 4,12,100717526-101128641,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA053412,Uncertain,,,,Renal cancer:5.48e-5 (favourable),Mixed,Group enriched,6,"adrenal gland: 17.6;cerebral cortex: 10.0;cervix, uterine: 12.6;endometrium: 8.4;ovary: 10.9;prostate: 11.7;seminal vesicle: 11.4",testis: 2.0,Cell line enhanced,,fHDF/TERT166: 14.2;SK-MEL-30: 13.3;TIME: 26.1;WM-115: 10.6
147,AP3B2,NAPTB,ENSG00000103723,Adaptor related protein complex 3 beta 2 subunit,15,82659281-82709914,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039467, HPA039818",Enhanced,,,,,Mixed,Group enriched,6,cerebral cortex: 36.2;parathyroid gland: 7.4,adrenal gland: 3.8,Cell line enhanced,,RT4: 11.4;SCLC-21H: 26.6;SH-SY5Y: 18.5
148,ARSF,,ENSG00000062096,Arylsulfatase F,X,3041471-3112726,Predicted membrane proteins,Evidence at protein level,HPA000549,,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,6,adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.0;esophagus: 2.3;kidney: 8.0;skin: 6.7,liver: 0.6,Not detected,,
149,ASIC2,"ACCN, ACCN1, ASIC2a, BNaC1, BNC1, hBNaC1, MDEG",ENSG00000108684,Acid sensing ion channel subunit 2,17,33013087-34174964,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA052112,Enhanced,,,,,Tissue enhanced,Group enriched,6,"cerebral cortex: 8.6;cervix, uterine: 3.9;endometrium: 6.4;smooth muscle: 2.2",adrenal gland: 0.8,Cell line enhanced,,NTERA-2: 1.1
150,ASTN1,ASTN,ENSG00000152092,Astrotactin 1,1,176857302-177164973,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA074112,,,Approved,Golgi apparatus<br>Vesicles,,Tissue enriched,Group enriched,6,adrenal gland: 19.6;cerebral cortex: 66.8,ovary: 7.4,Cell line enhanced,,Karpas-707: 4.1;NTERA-2: 4.4;SCLC-21H: 3.2;U-2 OS: 3.6;U-266/84: 14.7
151,ATP1A2,"FHM2, MHP2",ENSG00000018625,ATPase Na+/K+ transporting subunit alpha 2,1,160115759-160143591,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB022230,Approved,,,,,Tissue enriched,Group enriched,6,cerebral cortex: 434.2;skeletal muscle: 307.0,heart muscle: 57.5,Cell line enhanced,,AF22: 50.7;HHSteC: 12.3;RH-30: 16.2;U-87 MG: 10.1
152,ATP8A2,"ATPIB, ML-1",ENSG00000132932,ATPase phospholipid transporting 8A2,13,25372071-26025851,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA039926, HPA040033",Approved,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Group enriched,6,cerebral cortex: 26.4;testis: 10.7,adrenal gland: 2.9,Cell line enhanced,,HMC-1: 19.3;SCLC-21H: 3.9
153,C2CD4C,"FAM148C, KIAA1957, NLF3",ENSG00000183186,C2 calcium dependent domain containing 4C,19,405438-409170,Predicted intracellular proteins,Evidence at protein level,HPA055915,Uncertain,,Approved,Vesicles,,Tissue enhanced,Group enriched,6,adipose tissue: 2.6;cerebral cortex: 10.6;gallbladder: 4.4,endometrium: 0.9,Cell line enhanced,,HDLM-2: 5.9;NTERA-2: 6.2;SCLC-21H: 13.0;U-2 OS: 6.8
154,CACNB1,CACNLB1,ENSG00000067191,Calcium voltage-gated channel auxiliary subunit beta 1,17,39173456-39197703,"FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA023343,Approved,,,,Endometrial cancer:3.80e-4 (unfavourable),Mixed,Group enriched,6,cerebral cortex: 46.7;skeletal muscle: 108.5,skin: 12.3,Mixed,,
155,CDH22,"C20orf25, dJ998H6.1",ENSG00000149654,Cadherin 22,20,46173733-46308498,Predicted membrane proteins,Evidence at transcript level,HPA012164,Uncertain,,,,,Mixed,Group enriched,6,adrenal gland: 2.0;cerebral cortex: 10.2;fallopian tube: 2.3;skin: 5.1,"prostate,seminal vesicle,testis: 0.7",Cell line enriched,23.0,SCLC-21H: 3.7
156,CELF3,"BRUNOL1, CAGH4, ERDA4, MGC57297, TNRC4",ENSG00000159409,CUGBP Elav-like family member 3,1,151702404-151716814,Predicted intracellular proteins,Evidence at protein level,HPA006292,Uncertain,,Approved,Nucleoplasm,,Group enriched,Group enriched,6,adrenal gland: 15.2;cerebral cortex: 51.7,stomach: 5.5,Group enriched,10.0,SCLC-21H: 50.0;SH-SY5Y: 31.5
157,CELSR3,"ADGRC3, CDHF11, EGFL1, FMI1, HFMI1, MEGF2",ENSG00000008300,Cadherin EGF LAG seven-pass G-type receptor 3,3,48636469-48662915,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA062866,Approved,,,,,Mixed,Group enriched,6,adrenal gland: 1.6;cerebral cortex: 5.9;testis: 3.5,"parathyroid gland,stomach: 0.6",Cell line enhanced,,SH-SY5Y: 19.4;SiHa: 17.5
158,CLVS2,"bA160A10.4, C6orf212, C6orf213, RLBP1L2",ENSG00000146352,Clavesin 2,6,122995971-123072927,Predicted intracellular proteins,Evidence at protein level,HPA043764,Uncertain,,,,,Tissue enhanced,Group enriched,6,cerebral cortex: 15.4;prostate: 5.0,endometrium: 1.7,Group enriched,8.0,HEL: 10.9;SCLC-21H: 10.7
159,COL9A3,"DJ885L7.4.1, EDM3, FLJ90759, IDD, MED",ENSG00000092758,Collagen type IX alpha 3 chain,20,62816244-62841159,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040125, HPA058323",Supported,,Approved,Nucleoplasm<br>Intermediate filaments,,Mixed,Group enriched,6,cerebral cortex: 7.5;salivary gland: 10.5;testis: 6.3;thyroid gland: 19.1,seminal vesicle: 1.8,Group enriched,6.0,BEWO: 139.2;Hep G2: 40.1;SK-MEL-30: 37.9;WM-115: 57.3
160,CPNE6,,ENSG00000100884,Copine 6,14,24070837-24078100,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA031636,Approved,,,,,Tissue enhanced,Group enriched,6,cerebral cortex: 88.0;seminal vesicle: 35.2,kidney: 9.7,Cell line enhanced,,U-266/84: 1.3
161,CRYM,DFNA40,ENSG00000103316,Crystallin mu,16,21238874-21303083,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019086, HPA030619",Enhanced,,Supported,Cytosol,,Tissue enhanced,Group enriched,6,cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8,lung: 5.7,Cell line enhanced,,HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7
162,DOCK3,"KIAA0299, MOCA, PBP",ENSG00000088538,Dedicator of cytokinesis 3,3,50675241-51384198,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA037543, HPA037544",Approved,,Enhanced,Cytosol,,Tissue enhanced,Group enriched,6,cerebral cortex: 33.7;parathyroid gland: 12.6;testis: 8.5;thyroid gland: 15.1,adrenal gland: 3.0,Cell line enhanced,,AN3-CA: 5.9;U-87 MG: 8.0
163,EEF1A2,"EEF1AL, HS1, STN, STNL",ENSG00000101210,Eukaryotic translation elongation factor 1 alpha 2,20,63488013-63499315,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB034019, HPA051759, HPA053862, HPA056990",Approved,,Enhanced,Nucleoli<br>Cytosol,"Endometrial cancer:2.90e-5 (unfavourable), Head and neck cancer:9.11e-4 (unfavourable)",Expressed in all,Group enriched,6,cerebral cortex: 409.3;heart muscle: 425.6;skeletal muscle: 1372.7,adrenal gland: 127.7,Cell line enhanced,,MCF7: 899.8;SCLC-21H: 694.7;T-47d: 410.5;U-2 OS: 431.5
164,ERICH3,"C1orf173, DKFZp547I048, RP11-653A5.1",ENSG00000178965,Glutamate rich 3,1,74568111-74673738,Predicted intracellular proteins,Evidence at protein level,HPA028655,Approved,,,,Endometrial cancer:1.56e-5 (favourable),Tissue enhanced,Group enriched,6,"cerebral cortex: 18.9;cervix, uterine: 8.6;fallopian tube: 27.7;testis: 43.1",lung: 4.2,Not detected,,
165,FAM133A,"CT115, FLJ37659, RP1-32F7.2",ENSG00000179083,Family with sequence similarity 133 member A,X,93674013-93712274,Predicted intracellular proteins,Evidence at protein level,"HPA066175, HPA069513",,,Approved,Nucleus<br>Nucleoli,,Mixed,Group enriched,6,cerebral cortex: 5.3;testis: 14.1,adrenal gland: 1.5,Cell line enhanced,,Karpas-707: 33.0;U-2197: 22.2;U-266/70: 27.2;U-266/84: 58.1
166,FAM184B,KIAA1276,ENSG00000047662,Family with sequence similarity 184 member B,4,17629306-17781512,Predicted intracellular proteins,Evidence at protein level,"HPA044119, HPA048458",Enhanced,,,,,Mixed,Group enriched,6,cerebral cortex: 2.6;skeletal muscle: 1.4,"kidney,parathyroid gland,skin: 0.3",Cell line enhanced,,SCLC-21H: 2.5
167,FMN2,,ENSG00000155816,Formin 2,1,240014348-240475189,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA050649,,,Approved,Plasma membrane<br>Actin filaments,,Group enriched,Group enriched,6,cerebral cortex: 53.8;parathyroid gland: 33.5,adrenal gland: 7.0,Cell line enhanced,,BJ: 60.2;fHDF/TERT166: 54.7;LHCN-M2: 63.8;U-138 MG: 48.9;WM-115: 77.8
168,GALNT13,"GalNAc-T13, KIAA1918",ENSG00000144278,Polypeptide N-acetylgalactosaminyltransferase 13,2,153871913-154453849,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA060775,Approved,,,,,Tissue enriched,Group enriched,6,adrenal gland: 6.6;cerebral cortex: 32.7,prostate: 3.5,Cell line enhanced,,SH-SY5Y: 46.7;WM-115: 33.1
169,GAREM2,"FAM59B, FLJ00375, GAREML, KIAA2038",ENSG00000157833,GRB2 associated regulator of MAPK1 subtype 2,2,26173091-26189663,Predicted intracellular proteins,Evidence at protein level,HPA071575,,,Approved,Cytosol,,Mixed,Group enriched,6,cerebral cortex: 23.0;parathyroid gland: 17.8,smooth muscle: 3.4,Cell line enhanced,,HAP1: 17.3;U-2 OS: 14.6
170,GJD2,"CX36, GJA9",ENSG00000159248,Gap junction protein delta 2,15,34751032-34754965,Predicted membrane proteins,Evidence at protein level,HPA014355,Uncertain,,,,,Tissue enriched,Group enriched,6,adrenal gland: 7.9;cerebral cortex: 1.9,pancreas: 0.8,Not detected,,
171,GLRA3,,ENSG00000145451,Glycine receptor alpha 3,4,174636914-174829314,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,6,breast: 2.6;cerebral cortex: 9.1,adrenal gland: 1.0,Cell line enhanced,,Karpas-707: 1.4
172,GPR137C,"DKFZp762F0713, TM7SF1L2",ENSG00000180998,G protein-coupled receptor 137C,14,52553148-52637713,Predicted membrane proteins,Evidence at transcript level,"HPA003640, HPA030763",Uncertain,,Approved,Vesicles,,Mixed,Group enriched,6,cerebral cortex: 18.0;epididymis: 10.8;testis: 6.8,gallbladder: 2.1,Mixed,,
173,GPR162,"A-2, GRCA",ENSG00000250510,G protein-coupled receptor 162,12,6821545-6829972,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA055135,Enhanced,,Approved,Microtubule organizing center,"Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)",Tissue enriched,Group enriched,6,cerebral cortex: 84.3;fallopian tube: 29.4,lung: 9.5,Cell line enhanced,,AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2
174,GPR83,GPR72,ENSG00000123901,G protein-coupled receptor 83,11,94377311-94401419,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Group enriched,6,adrenal gland: 1.0;cerebral cortex: 4.6;thyroid gland: 5.1,"skin,testis: 0.5",Cell line enhanced,,CACO-2: 1.4
175,HCN4,,ENSG00000138622,Hyperpolarization activated cyclic nucleotide gated potassium channel 4,15,73319859-73369264,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Group enriched,Group enriched,6,cerebral cortex: 1.4;heart muscle: 1.5;testis: 6.7,adrenal gland: 0.5,Cell line enhanced,,AF22: 1.2;CACO-2: 1.3;NTERA-2: 4.7;U-2 OS: 2.1
176,KIF6,"C6orf102, dJ1043E3.1, dJ137F1.4, dJ188D3.1, DKFZp451I2418, MGC33317",ENSG00000164627,Kinesin family member 6,6,39329990-39725405,Predicted intracellular proteins,Evidence at protein level,"HPA038811, HPA058624",Enhanced,,Approved,Centrosome,,Mixed,Group enriched,6,cerebral cortex: 7.0;fallopian tube: 6.0;testis: 9.6,lung: 1.2,Cell line enhanced,,RPMI-8226: 6.3;SCLC-21H: 14.3;SK-MEL-30: 4.0
177,KLHL32,"BKLHD5, KIAA1900",ENSG00000186231,Kelch like family member 32,6,96924620-97140754,Predicted intracellular proteins,Evidence at protein level,HPA039150,Enhanced,,,,,Mixed,Group enriched,6,cerebral cortex: 25.3;fallopian tube: 10.3,testis: 3.1,Cell line enhanced,,Daudi: 2.3;HDLM-2: 4.1;SCLC-21H: 2.1;U-266/70: 1.7
178,KLRC2,"CD159c, NKG2-C",ENSG00000205809,Killer cell lectin like receptor C2,12,10426854-10442300,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058052,,,Approved,Plasma membrane,,Tissue enriched,Group enriched,6,cerebral cortex: 17.3;spleen: 8.1,stomach: 2.1,Cell line enhanced,,HEL: 5.2;HeLa: 11.9;HSkMC: 3.0;U-87 MG: 2.8
179,LMTK3,"KIAA1883, LMR3, PPP1R101, TYKLM3",ENSG00000142235,Lemur tyrosine kinase 3,19,48485271-48513189,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA040203, HPA077070",Enhanced,,Approved,Nucleoplasm<br>Cell Junctions,Renal cancer:3.18e-8 (favourable),Mixed,Group enriched,6,cerebral cortex: 20.3;parathyroid gland: 4.9,duodenum: 2.2,Cell line enhanced,,HMC-1: 6.1;SK-BR-3: 6.2;U-266/70: 5.9
180,LRRC63,RP11-139H14.4,ENSG00000173988,Leucine rich repeat containing 63,13,46211943-46277366,Predicted intracellular proteins,Evidence at transcript level,"HPA039318, HPA039763",Uncertain,,Approved,Golgi apparatus,,Not detected,Group enriched,6,cerebral cortex: 1.1;epididymis: 1.7;testis: 2.4,fallopian tube: 0.3,Cell line enhanced,,HDLM-2: 1.1
181,MAGEE2,HCA3,ENSG00000186675,MAGE family member E2,X,75782988-75785236,Predicted intracellular proteins,Evidence at transcript level,HPA030625,Uncertain,,,,,Tissue enriched,Group enriched,6,adrenal gland: 1.0;cerebral cortex: 3.3,"endometrium,ovary,prostate,rectum,smooth muscle: 0.3",Not detected,,
182,MEGF11,"DKFZp434L121, KIAA1781",ENSG00000157890,Multiple EGF like domains 11,15,65895079-66253747,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA017982,Uncertain,,,,,Tissue enhanced,Group enriched,6,cerebral cortex: 13.0;fallopian tube: 12.3,testis: 1.9,Cell line enhanced,,AN3-CA: 3.1;HEK93: 2.4;RPTEC TERT1: 7.0;SCLC-21H: 8.5
183,NEU4,,ENSG00000204099,Neuraminidase 4,2,241808825-241817413,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037394, HPA037395",Uncertain,,,,,Group enriched,Group enriched,6,bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3,"fallopian tube,gallbladder: 0.7",Group enriched,20.0,Hep G2: 26.3;HMC-1: 45.5
184,NTNG2,"KIAA1857, Lmnt2, NTNG1",ENSG00000196358,Netrin G2,9,132161676-132244534,Predicted secreted proteins,Evidence at protein level,"HPA061242, HPA065089, HPA071290",Approved,,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytokinetic bridge<br>Midbody ring<br>Cytosol,Prostate cancer:6.06e-4 (favourable),Mixed,Group enriched,6,bone marrow: 26.5;cerebral cortex: 18.5;parathyroid gland: 16.3;prostate: 10.0,spleen: 3.1,Cell line enhanced,,HMC-1: 14.1;NB-4: 24.3;U-937: 7.7
185,OLR1,"CLEC8A, LOX-1, SCARE1",ENSG00000173391,Oxidized low density lipoprotein receptor 1,12,10158301-10172138,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA050798,,,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,Head and neck cancer:8.24e-5 (unfavourable),Expressed in all,Group enriched,6,appendix: 41.3;cerebral cortex: 32.7;lung: 146.3;placenta: 160.9,bone marrow: 15.8,Cell line enhanced,,CACO-2: 102.6;HHSteC: 104.1;SiHa: 261.9;SK-BR-3: 72.4
186,PLPPR1,"FLJ20300, LPPR1, MGC26189, PRG-3",ENSG00000148123,Phospholipid phosphatase related 1,9,101028709-101325135,Predicted membrane proteins,Evidence at protein level,"HPA014760, HPA014968, HPA014979",Supported,,Supported,Nucleoplasm,Lung cancer:1.37e-4 (favourable),Group enriched,Group enriched,6,cerebral cortex: 23.8;kidney: 15.8,epididymis: 3.3,Cell line enhanced,,Hep G2: 2.1;SCLC-21H: 6.4
187,PPFIA3,"KIAA0654, LPNA3, MGC126567, MGC126569",ENSG00000177380,PTPRF interacting protein alpha 3,19,49119389-49151026,Predicted intracellular proteins,Evidence at protein level,"HPA043567, HPA050340",Enhanced,,Uncertain,Nucleoli fibrillar center<br>Vesicles,"Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable)",Expressed in all,Group enriched,6,cerebral cortex: 21.5;skin: 20.2,parathyroid gland: 3.6,Cell line enhanced,,PC-3: 33.5
188,PRLHR,"GPR10, PrRPR",ENSG00000119973,Prolactin releasing hormone receptor,10,118589989-118595699,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA039361,Supported,,,,,Not detected,Group enriched,6,adrenal gland: 6.7;cerebral cortex: 3.7;endometrium: 4.0;smooth muscle: 5.5,seminal vesicle: 0.7,Not detected,,
189,RTBDN,FLJ36353,ENSG00000132026,Retbindin,19,12825478-12835428,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA052511,,,Approved,Endoplasmic reticulum,,Mixed,Group enriched,6,adrenal gland: 4.6;cerebral cortex: 14.6;testis: 3.5,stomach: 1.2,Cell line enhanced,,SCLC-21H: 9.8;SH-SY5Y: 5.8;U-266/84: 16.0
190,RTN4RL2,"NgR2, NGRH1",ENSG00000186907,Reticulon 4 receptor-like 2,11,57460549-57477534,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:3.05e-7 (unfavourable),Expressed in all,Group enriched,6,cerebral cortex: 48.7;thyroid gland: 36.2,"liver,parathyroid gland: 6.6",Cell line enhanced,,HMC-1: 38.9;Karpas-707: 48.5;REH: 38.5;RPMI-8226: 93.4
191,SH3TC2,"CMT4C, KIAA1985",ENSG00000169247,SH3 domain and tetratricopeptide repeats 2,5,148923639-149063163,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA037683, HPA037684",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,6,cerebral cortex: 3.0;placenta: 2.8;testis: 8.8,"cervix, uterine,heart muscle: 0.7",Cell line enhanced,,RT4: 6.6;SK-MEL-30: 5.9;WM-115: 8.2
192,SLC4A3,"AE3, SLC2C",ENSG00000114923,Solute carrier family 4 member 3,2,219627327-219641980,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA063498,,,Approved,Nucleoplasm,Urothelial cancer:4.12e-4 (unfavourable),Expressed in all,Group enriched,6,cerebral cortex: 30.0;heart muscle: 119.1;ovary: 47.7,testis: 10.9,Mixed,,
193,SLC8A3,NCX3,ENSG00000100678,Solute carrier family 8 member A3,14,70044217-70189070,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,6,cerebral cortex: 16.3;skeletal muscle: 6.1,adrenal gland: 1.7,Cell line enhanced,,AF22: 4.3;LHCN-M2: 6.7;SH-SY5Y: 27.3
194,SOX21,SOX25,ENSG00000125285,SRY-box 21,13,94709622-94712399,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA048337, HPA064084",Approved,,Approved,Nucleus,"Glioma:1.34e-4 (favourable), Cervical cancer:7.60e-4 (favourable)",Tissue enhanced,Group enriched,6,cerebral cortex: 17.9;esophagus: 6.9;skin: 19.4;stomach: 33.4,tonsil: 3.1,Cell line enhanced,,AF22: 80.6;HAP1: 12.8;NTERA-2: 22.0;PC-3: 11.6
195,SRSF12,"SFRS13B, SFRS19, SRrp35",ENSG00000154548,Serine and arginine rich splicing factor 12,6,89095959-89118081,Predicted intracellular proteins,Evidence at protein level,HPA049782,Approved,,,,,Mixed,Group enriched,6,cerebral cortex: 6.9;testis: 20.9,"parathyroid gland,thyroid gland: 2.1",Cell line enhanced,,AF22: 9.1;AN3-CA: 8.8;HAP1: 7.7;HEK93: 7.0;REH: 6.9;SCLC-21H: 9.5;SH-SY5Y: 8.4
196,STAC2,24b2,ENSG00000141750,SH3 and cysteine rich domain 2,17,39210536-39225872,Predicted intracellular proteins,Evidence at protein level,HPA017288,,,Approved,Nucleoplasm<br>Vesicles,"Endometrial cancer:4.05e-5 (unfavourable), Glioma:5.04e-4 (unfavourable), Ovarian cancer:6.66e-4 (unfavourable)",Group enriched,Group enriched,6,breast: 32.0;cerebral cortex: 30.1;epididymis: 13.8;seminal vesicle: 35.6,skin: 4.5,Cell line enhanced,,HeLa: 22.2;hTEC/SVTERT24-B: 4.8;U-87 MG: 14.4
197,TCEAL6,WEX2,ENSG00000204071,Transcription elongation factor A like 6,X,102140476-102142970,Predicted intracellular proteins,Evidence at protein level,"HPA045564, HPA058982",Supported,,,,,Tissue enriched,Group enriched,6,adrenal gland: 14.3;cerebral cortex: 63.5;testis: 34.6,endometrium: 5.8,Not detected,,
198,TMEM155,FLJ30834,ENSG00000164112,Transmembrane protein 155,4,121758933-121765427,Predicted secreted proteins,Evidence at transcript level,HPA077585,Approved,,,,,Mixed,Group enriched,6,cerebral cortex: 27.6;placenta: 5.7,lymph node: 3.0,Cell line enhanced,,fHDF/TERT166: 4.0;HAP1: 2.2;LHCN-M2: 5.5;MOLT-4: 5.1
199,TUBA8,TUBAL2,ENSG00000183785,Tubulin alpha 8,22,18110331-18146554,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043684, CAB046031, HPA063394",Approved,,Supported,Microtubules,,Not detected,Group enriched,6,cerebral cortex: 28.6;heart muscle: 83.0;skeletal muscle: 121.7;testis: 47.4,thyroid gland: 11.2,Group enriched,5.0,NB-4: 19.8;SCLC-21H: 17.4;TIME: 31.1
200,VAT1L,KIAA1576,ENSG00000171724,Vesicle amine transport 1 like,16,77788530-77980107,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA044061, CAB046032",Enhanced,,Approved,Cytosol,Renal cancer:3.01e-6 (unfavourable),Tissue enhanced,Group enriched,6,adrenal gland: 90.6;cerebral cortex: 38.8,heart muscle: 10.3,Cell line enhanced,,BJ hTERT+: 55.2;fHDF/TERT166: 29.2;NTERA-2: 79.1;U-87 MG: 80.3
201,ZIC4,,ENSG00000174963,Zic family member 4,3,147386046-147406860,"Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at transcript level,HPA030194,Uncertain,,Approved,Nucleus<br>Cytosol,,Mixed,Group enriched,6,cerebral cortex: 4.3;skin: 1.4,skeletal muscle: 0.5,Cell line enhanced,,AF22: 17.0;SH-SY5Y: 5.5
202,ANOS1,"ADMLX, KAL, KAL1, KALIG-1, WFDC19",ENSG00000011201,Anosmin 1,X,8528874-8732186,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,5,cerebral cortex: 32.3;lung: 64.7;parathyroid gland: 48.5;thyroid gland: 15.5,testis: 7.3,Group enriched,5.0,NTERA-2: 36.7;U-2 OS: 18.3
203,APLNR,"AGTRL1, APJ, APJR, FLJ90771",ENSG00000134817,Apelin receptor,11,57233577-57237314,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,CAB025842,Approved,,,,,Expressed in all,Group enriched,5,cerebral cortex: 82.7;placenta: 146.8;spleen: 161.6,adipose tissue: 24.9,Group enriched,22.0,AF22: 6.2;HEL: 5.0;K-562: 1.5;NTERA-2: 1.8
204,CALN1,,ENSG00000183166,Calneuron 1,7,71779491-72447151,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036278, HPA036708",Approved,,Uncertain,Vesicles<br>Plasma membrane,,Mixed,Group enriched,5,adrenal gland: 14.7;cerebral cortex: 46.4,testis: 6.0,Cell line enhanced,,Karpas-707: 33.8;NTERA-2: 6.0;REH: 6.4;SCLC-21H: 7.8;U-2 OS: 7.6
205,CCK,,ENSG00000187094,Cholecystokinin,3,42257825-42266207,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA045039, HPA069515",Enhanced,Supported,,,,Group enriched,Group enriched,5,cerebral cortex: 133.7;duodenum: 116.2;prostate: 31.6,small intestine: 17.7,Group enriched,6.0,CAPAN-2: 8.5;RPTEC TERT1: 18.9
206,DBX2,FLJ16139,ENSG00000185610,Developing brain homeobox 2,12,45014672-45051099,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA066053,Uncertain,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 4.1;testis: 1.2,skin: 0.5,Not detected,,
207,DNAJC18,MGC29463,ENSG00000170464,DnaJ heat shock protein family (Hsp40) member C18,5,139408588-139444491,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036538, HPA060154",Approved,,Supported,Cell Junctions,Pancreatic cancer:5.89e-4 (favourable),Mixed,Group enriched,5,cerebral cortex: 30.2;testis: 115.6,ovary: 13.8,Mixed,,
208,FAM107A,"DRR1, TU3A",ENSG00000168309,Family with sequence similarity 107 member A,3,58564117-58627610,Predicted intracellular proteins,Evidence at protein level,HPA055888,Enhanced,,Supported,Nuclear speckles,"Liver cancer:3.38e-4 (favourable), Endometrial cancer:3.56e-4 (unfavourable)",Tissue enriched,Group enriched,5,cerebral cortex: 485.7;fallopian tube: 125.1,epididymis: 57.5,Group enriched,6.0,ASC diff: 12.6;HUVEC TERT2: 48.1
209,GJB6,"CX30, DFNA3, ED2, EDH, HED",ENSG00000121742,Gap junction protein beta 6,13,20221971-20232395,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA014846,,,Supported,Cell Junctions,,Tissue enhanced,Group enriched,5,bone marrow: 48.1;cerebral cortex: 39.4;esophagus: 150.1;skin: 32.1,tonsil: 12.2,Cell line enriched,9.0,RT4: 133.4
210,GRIN3A,GluN3A,ENSG00000198785,Glutamate ionotropic receptor NMDA type subunit 3A,9,101569353-101738580,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,5,"cerebral cortex: 12.3;cervix, uterine: 2.5",seminal vesicle: 1.3,Cell line enriched,6.0,SCLC-21H: 2.1
211,GRM1,"GPRC1A, mGlu1, MGLUR1, PPP1R85",ENSG00000152822,Glutamate metabotropic receptor 1,6,146027646-146437598,"Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA015701,Approved,,Approved,Vesicles,,Not detected,Group enriched,5,cerebral cortex: 7.0;heart muscle: 1.7,kidney: 0.8,Not detected,,
212,HS3ST5,3-OST-5,ENSG00000249853,Heparan sulfate-glucosamine 3-sulfotransferase 5,6,114055586-114343045,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021823, HPA064677",Approved,,,,,Not detected,Group enriched,5,cerebral cortex: 6.2;seminal vesicle: 2.2;skeletal muscle: 1.3,adrenal gland: 0.6,Cell line enhanced,,PC-3: 4.2;RT4: 6.8;SCLC-21H: 19.0
213,IGDCC3,"HsT18880, PUNC",ENSG00000174498,Immunoglobulin superfamily DCC subclass member 3,15,65327127-65378040,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA015246,Approved,,,,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.3;parathyroid gland: 14.6;placenta: 8.5;testis: 5.0,thyroid gland: 1.5,Cell line enhanced,,AF22: 103.7;CACO-2: 22.5;Hep G2: 58.8
214,ISLR2,KIAA1465,ENSG00000167178,Immunoglobulin superfamily containing leucine rich repeat 2,15,74100311-74138540,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012930, HPA067333",Uncertain,,,,,Mixed,Group enriched,5,cerebral cortex: 31.1;testis: 14.8,endometrium: 4.5,Group enriched,13.0,SCLC-21H: 68.2;SH-SY5Y: 91.6
215,KCNH3,"BEC1, elk2, Kv12.2",ENSG00000135519,Potassium voltage-gated channel subfamily H member 3,12,49539157-49558308,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA051088,Uncertain,,Approved,Nucleus<br>Mitochondria,,Tissue enhanced,Group enriched,5,cerebral cortex: 24.2;fallopian tube: 7.1;parathyroid gland: 4.9,adrenal gland: 2.2,Cell line enhanced,,A549: 7.6;RPTEC TERT1: 7.7;U-2 OS: 11.2
216,KCNJ10,"Kir1.2, Kir4.1",ENSG00000177807,Potassium voltage-gated channel subfamily J member 10,1,159998651-160070483,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA078302,Enhanced,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 124.7;kidney: 30.6,spleen: 14.5,Cell line enhanced,,Hep G2: 4.5;SK-MEL-30: 1.6;U-266/70: 1.6
217,KCNT1,"KCa4.1, KIAA1422, SLACK, Slo2.2",ENSG00000107147,Potassium sodium-activated channel subfamily T member 1,9,135702185-135795508,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA059880,Uncertain,,,,,Tissue enhanced,Group enriched,5,cerebral cortex: 11.6;ovary: 3.9;skeletal muscle: 3.8;spleen: 6.8,testis: 1.2,Cell line enhanced,,RPMI-8226: 1.2;SCLC-21H: 3.0
218,KLK6,"Bssp, Klk7, neurosin, PRSS18, PRSS9",ENSG00000167755,Kallikrein related peptidase 6,19,50958631-50969673,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA051837,,,Supported,Nucleoplasm<br>Nuclear membrane<br>Cytokinetic bridge,"Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable)",Tissue enhanced,Group enriched,5,cerebral cortex: 78.6;esophagus: 63.0;fallopian tube: 44.9;tonsil: 31.3,kidney: 10.2,Group enriched,15.0,A-431: 496.5;CAPAN-2: 1158.9
219,LUZP2,,ENSG00000187398,Leucine zipper protein 2,11,24496970-25082631,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039007, HPA046161",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Group enriched,Group enriched,5,adrenal gland: 8.6;cerebral cortex: 33.0,prostate: 3.8,Group enriched,6.0,HaCaT: 9.2;HAP1: 5.4
220,MGAT4C,HGNT-IV-H,ENSG00000182050,MGAT4 family member C,12,85955666-86838904,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA016418,Approved,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 5.9;epididymis: 6.7;testis: 5.5;thyroid gland: 15.9,adrenal gland: 1.6,Group enriched,13.0,NTERA-2: 8.7;SCLC-21H: 4.4
221,NGB,,ENSG00000165553,Neuroglobin,14,77265483-77271312,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA042615, HPA058596",Enhanced,,,,,Tissue enhanced,Group enriched,5,adrenal gland: 10.1;cerebral cortex: 4.8;fallopian tube: 2.2,pancreas: 1.0,Group enriched,30.0,RPMI-8226: 4.3;SCLC-21H: 14.4
222,NKAIN1,"FAM77C, FLJ12650",ENSG00000084628,Sodium/potassium transporting ATPase interacting 1,1,31179745-31239554,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA006873,Uncertain,,,,,Group enriched,Group enriched,5,adrenal gland: 13.9;cerebral cortex: 13.1;epididymis: 4.4;skeletal muscle: 7.4,prostate: 1.9,Cell line enhanced,,AF22: 23.5;AN3-CA: 36.7;NTERA-2: 101.7;SCLC-21H: 35.5;SH-SY5Y: 50.9
223,NNAT,Peg5,ENSG00000053438,Neuronatin,20,37521215-37523693,Predicted membrane proteins,Evidence at transcript level,,,,,,,Group enriched,Group enriched,5,cerebral cortex: 157.6;placenta: 147.3,adipose tissue: 27.9,Cell line enriched,28.0,SH-SY5Y: 735.9
224,NOG,"SYM1, SYNS1",ENSG00000183691,Noggin,17,56593699-56595590,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA061318,Approved,,,,"Pancreatic cancer:6.86e-5 (unfavourable), Endometrial cancer:6.66e-4 (favourable)",Mixed,Group enriched,5,cerebral cortex: 7.3;placenta: 15.8,lymph node: 2.2,Cell line enhanced,,EFO-21: 117.5;LHCN-M2: 32.2;PC-3: 35.7;U-2 OS: 40.3
225,NPAS1,"bHLHe11, MOP5, PASD5",ENSG00000130751,Neuronal PAS domain protein 1,19,47019820-47045775,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA043364, HPA072259",,Approved,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.9;skin: 4.4;spleen: 1.8;stomach: 2.6,lymph node: 0.6,Cell line enhanced,,HEK93: 10.1;NB-4: 11.4
226,PABPC1L2A,RBM32A,ENSG00000186288,Poly(A) binding protein cytoplasmic 1 like 2A,X,73077276-73079512,Predicted intracellular proteins,Evidence at transcript level,HPA041573,Approved,,,,,Tissue enriched,Group enriched,5,adrenal gland: 2.0;cerebral cortex: 6.7;prostate: 3.6;testis: 2.8,epididymis: 0.7,Cell line enhanced,,HeLa: 2.6;NTERA-2: 1.4
227,PABPC1L2B,RBM32B,ENSG00000184388,Poly(A) binding protein cytoplasmic 1 like 2B,X,73003517-73005713,Predicted intracellular proteins,Evidence at transcript level,HPA041573,Approved,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 8.7;prostate: 4.6,testis: 1.2,Cell line enhanced,,NTERA-2: 1.6
228,PCDH10,"KIAA1400, OL-PCDH",ENSG00000138650,Protocadherin 10,4,133149315-133208606,Predicted membrane proteins,Evidence at protein level,"HPA011220, HPA073462",Approved,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,,Tissue enhanced,Group enriched,5,cerebral cortex: 62.0;placenta: 36.7;prostate: 17.6;seminal vesicle: 24.5,adrenal gland: 6.8,Cell line enhanced,,HUVEC TERT2: 23.1;MOLT-4: 19.4;TIME: 45.4;U-138 MG: 14.3
229,PNMAL2,KIAA1183,ENSG00000204851,Paraneoplastic Ma antigen family like 2,19,46486906-46496498,Predicted intracellular proteins,Evidence at protein level,HPA054810,Enhanced,,,,,Mixed,Group enriched,5,adrenal gland: 12.1;cerebral cortex: 32.9,ovary: 4.3,Cell line enhanced,,AF22: 1.2;AN3-CA: 1.4;SH-SY5Y: 1.3
230,PPM1E,"CaMKP-N, KIAA1072, POPX1, PP2CH",ENSG00000175175,"Protein phosphatase, Mg2+/Mn2+ dependent 1E",17,58755869-58985176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018462, HPA019263",Approved,,Approved,Nucleus<br>Nucleoli,,Tissue enhanced,Group enriched,5,adrenal gland: 7.3;cerebral cortex: 20.5;testis: 12.1,fallopian tube: 2.4,Cell line enhanced,,AF22: 12.1;HAP1: 20.6;SCLC-21H: 10.7;SH-SY5Y: 19.9
231,PPP1R17,"C7orf16, GSBS",ENSG00000106341,Protein phosphatase 1 regulatory subunit 17,7,31686715-31708455,Predicted intracellular proteins,Evidence at protein level,"HPA047819, HPA073123",Supported,,Supported,Nucleoplasm,,Tissue enhanced,Group enriched,5,adrenal gland: 4.8;cerebral cortex: 2.6;testis: 1.1,lung: 0.5,Group enriched,225.0,NTERA-2: 33.8;SCLC-21H: 120.1
232,PTPRT,"KIAA0283, RPTPrho",ENSG00000196090,"Protein tyrosine phosphatase, receptor type T",20,42072752-43189970,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA017336, CAB069423",Approved,,,,,Tissue enhanced,Group enriched,5,cerebral cortex: 24.3;fallopian tube: 17.4,placenta: 4.0,Cell line enhanced,,BEWO: 1.1
233,RAB6B,,ENSG00000154917,"RAB6B, member RAS oncogene family",3,133824239-133895836,Predicted intracellular proteins,Evidence at protein level,"CAB017713, HPA059131",Uncertain,,Approved,Golgi apparatus,"Pancreatic cancer:3.97e-6 (favourable), Endometrial cancer:9.01e-4 (unfavourable)",Expressed in all,Group enriched,5,cerebral cortex: 211.3;parathyroid gland: 77.1,fallopian tube: 26.2,Cell line enhanced,,HEL: 207.7;K-562: 49.3;SCLC-21H: 56.7
234,RBFOX1,"A2BP1, FOX-1, HRNBP1",ENSG00000078328,"RNA binding protein, fox-1 homolog 1",16,6019094-7713338,Predicted intracellular proteins,Evidence at protein level,HPA040809,Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,,Tissue enhanced,Group enriched,5,cerebral cortex: 110.5;skeletal muscle: 32.9,heart muscle: 13.9,Cell line enriched,18.0,RH-30: 26.2
235,RGS8,"MGC119067, MGC119068, MGC119069",ENSG00000135824,Regulator of G-protein signaling 8,1,182641816-182684576,Predicted intracellular proteins,Evidence at protein level,HPA076764,Supported,,,,,Group enriched,Group enriched,5,cerebral cortex: 5.3;testis: 4.9;thyroid gland: 11.3,adrenal gland: 1.3,Group enriched,5.0,AF22: 5.6;SCLC-21H: 18.7
236,SATB2,"FLJ21474, KIAA1034",ENSG00000119042,SATB homeobox 2,2,199269500-199471266,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001042, CAB023669, HPA029543, CAB062562, CAB067751, CAB068229, CAB068230, CAB068231",Enhanced,,Supported,Nucleoplasm,Renal cancer:5.37e-8 (favourable),Tissue enhanced,Group enriched,5,cerebral cortex: 22.7;colon: 34.1;rectum: 43.2,small intestine: 6.3,Mixed,,
237,SLC1A6,EAAT4,ENSG00000105143,Solute carrier family 1 member 6,19,14950034-15022990,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA041505, HPA044066",Enhanced,,Uncertain,Intermediate filaments,Urothelial cancer:6.88e-6 (unfavourable),Tissue enriched,Group enriched,5,cerebral cortex: 16.2;skin: 8.9;testis: 36.9,epididymis: 3.7,Group enriched,5.0,HAP1: 7.6;NTERA-2: 6.0;U-698: 19.3
238,SLC5A11,"KST1, SGLT6, SMIT2",ENSG00000158865,Solute carrier family 5 member 11,16,24845841-24911628,Predicted membrane proteins,Evidence at protein level,HPA035331,Uncertain,,Approved,Nucleus<br>Cytosol,,Mixed,Group enriched,5,cerebral cortex: 10.5;duodenum: 6.6;kidney: 6.1;small intestine: 15.2,breast: 1.7,Cell line enhanced,,BEWO: 1.7;Hep G2: 11.2;Karpas-707: 3.2
239,SLC6A1,"GABATHG, GABATR, GAT1",ENSG00000157103,Solute carrier family 6 member 1,3,10992724-11039247,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA013341, CAB022293",Enhanced,,Uncertain,Mitochondria,"Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable)",Group enriched,Group enriched,5,cerebral cortex: 119.4;liver: 50.4,parathyroid gland: 16.0,Not detected,,
240,SNCA,"alpha-synuclein, NACP, PARK1, PARK4, PD1",ENSG00000145335,Synuclein alpha,4,89724099-89838315,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA005459, CAB010877",Enhanced,,,,,Tissue enriched,Group enriched,5,bone marrow: 160.8;cerebral cortex: 459.2,endometrium: 57.1,Cell line enhanced,,HEL: 198.4;HUVEC TERT2: 218.9;SK-MEL-30: 203.3;TIME: 246.6
241,SYT14,"FLJ34198, sytXIV",ENSG00000143469,Synaptotagmin 14,1,209938174-210171389,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA036963,,,Supported,Vesicles,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.0;testis: 6.7;thyroid gland: 9.8,adrenal gland: 1.3,Cell line enhanced,,BJ hTERT+: 10.5;SCLC-21H: 7.8;TIME: 8.9;U-138 MG: 7.9
242,TMEM132E,DFNB99,ENSG00000181291,Transmembrane protein 132E,17,34580749-34639318,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA070608,Approved,,,,Renal cancer:1.55e-4 (unfavourable),Group enriched,Group enriched,5,cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.0;testis: 1.5,"cervix, uterine: 0.4",Cell line enriched,7.0,RPMI-8226: 31.6
243,TMEM233,IFITMD2,ENSG00000224982,Transmembrane protein 233,12,119593459-119643066,Predicted membrane proteins,Evidence at transcript level,HPA047506,Uncertain,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 16.2;skeletal muscle: 11.5;thyroid gland: 21.4,parathyroid gland: 3.1,Cell line enhanced,,hTEC/SVTERT24-B: 19.8;RH-30: 10.2;U-2197: 14.8;U-87 MG: 61.5
244,WASF1,"KIAA0269, SCAR1, WAVE, WAVE1",ENSG00000112290,WAS protein family member 1,6,110099819-110180004,Predicted intracellular proteins,Evidence at protein level,"HPA004105, CAB022161",Approved,Approved,,,"Liver cancer:2.82e-8 (unfavourable), Renal cancer:2.79e-5 (unfavourable)",Expressed in all,Group enriched,5,cerebral cortex: 138.9;testis: 149.9,ovary: 27.8,Mixed,,
245,WSCD2,KIAA0789,ENSG00000075035,WSC domain containing 2,12,108129471-108250537,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,"HPA013346, HPA048133",Approved,,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,5,"cerebral cortex: 14.1;cervix, uterine: 5.8;endometrium: 8.6;prostate: 7.1;seminal vesicle: 19.0;smooth muscle: 10.4;thyroid gland: 28.8",urinary bladder: 2.6,Cell line enriched,20.0,RT4: 26.6
